

The  
Patent  
Office

PCT/GB 00/01002  
17 MARCH 2000  
INVESTOR IN PEOPLE

GB 00/01002-09/936

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

**09/936572**

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

④


REC'D 24 MAY 2000	
WIPO	PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*AmBrenar*


Dated 31 March 2000

**THIS PAGE BLANK (USPTO)**



The  
Patent  
Office

1874999 8433265-1 003046  
P01/7700 0.00 - 990177.2



# Request for a grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference P006478GB ATM

2. Patent appl (The Patent) **9906177.2** 17 MAR 1999

3. Full name, address and postcode of the or of each applicant (underline all surnames)  
Oxford BioMedica (UK) Limited  
Medawar Centre  
Robert Robinson Avenue  
The Oxford Science Park  
Oxford  
OX4 4GA United Kingdom

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation United Kingdom

7223522001

4. Title of the invention Anti-Viral Vectors

5. Name of your agent (if you have one) D YOUNG & CO  
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode) 21 NEW FETTER LANE  
LONDON  
EC4A 1DA  
Patents ADP number (if you have one) 59006

6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and filing date of the earlier application	Number of earlier application	Date of filing (day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:  
a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant, or  
c) any named applicant is a corporate body.  
See note (d))

Yes

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 39

Claims(s) 3

Abstract 1

Drawing(s) 14

10. If you are also filing any of the following, state how many against each item.

Priority documents 0

Translations of priority documents 0

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 0

Request for preliminary examination and search (Patents Form 9/77) 0

Request for substantive examination (Patents Form 10/77) 0

Any other documents (please specify) No

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date

D. Young & Co.

17 03 99

D YOUNG & CO

Agents for the Applicants

12. Name and daytime telephone number of the person to contact in the United Kingdom

Dr A Maschio

01703 634816

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505

b) Write your answers in capital letters using black ink or you may type them

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

d) If you answered 'Yes' Patents Form 7/77 will need to be filed.

e) Once you have filled in the form you must remember to sign and date it.

f) For details of the fee and ways to pay please contact the Patent Office.

## ANTI-VIRAL VECTORS

### Field of the Invention

5 The present invention relates to novel viral vectors capable of delivering anti-viral inhibitory RNA molecules to target cells.

### Background to the Invention

10 The application of gene therapy to the treatment of AIDS and HIV infection has been discussed widely (Lever, 1995). The types of therapeutic gene proposed usually fall into one of two broad categories. In the first the gene encodes protein products that inhibit the virus in a number of possible ways. One example of such a protein is the RevM10 derivative of the HIV Rev protein. The RevM10 protein acts as a transdominant negative  
15 mutant and so competitively inhibits Rev function in the virus. Like many of the protein-based strategies, the RevM10 protein is a derivative of a native HIV protein. While this provides the basis for the anti-HIV effect, it also has serious disadvantages. In particular, this type of strategy demands that in the absence of the virus there is little or no expression of the gene. Otherwise, healthy cells harbouring the gene become a target for the host  
20 cytotoxic T lymphocyte (CTL) system, which recognises the foreign protein. The second broad category of therapeutic gene circumvents these CTL problems. The therapeutic gene encodes inhibitory RNA molecules; RNA is not a target for CTL recognition.

There are several types of inhibitory RNA molecules known: anti-sense RNA, ribozymes,  
25 competitive decoys and external guide sequences (EGSs).

External guide sequences, first identified by Forster and Altman (1990), are RNA sequences that are capable of directing the cellular protein RNase P to cleave a particular RNA sequence. *In vivo*, they are found as part of precursor tRNAs where they function to  
30 direct cleavage by the cellular riboprotein RNase P *in vivo* of the tRNA precursor to form mature tRNA. However, in principle, any RNA can be targeted by a custom-designed EGS RNA for specific cleavage by RNase P *in vitro* or *in vivo*. For example, Yuan *et al.* (1992)

demonstrate a reduction in the levels of chloramphenicol activity in cells in tissue culture as a result of introducing an appropriately designed EGS.

In recent years a number of laboratories have developed retroviral vector systems based on HIV. In the context of anti-HIV gene therapy these vectors have a number of advantages over the more conventional murine based vectors such as murine leukaemia virus (MLV) vectors. Firstly, HIV vectors would target precisely those cells that are susceptible to HIV infection. Secondly, the HIV-based vector would transduce cells such as macrophages that are normally refractory to transduction by murine vectors. Thirdly, the anti-HIV vector genome would be propagated through the CD4+ cell population by any virus (HIV) that escaped the therapeutic strategy. This is because the vector genome has the packaging signal that will be recognised by the viral particle packaging system. These various attributes make HIV-vectors a powerful tool in the field of anti-HIV gene therapy.

A combination of inhibitory RNA molecules and an HIV-based vector would be attractive as a therapeutic strategy. However, until now this has not been possible. Vector particle production takes place in producer cells which express the packaging components of the particles and package the vector genome. The inhibitory RNA sequences that are designed to destroy the viral RNA would therefore also interrupt the expression of the components of the HIV-based vector system during vector production. The present invention aims to overcome this problem.

#### Summary of the Invention

It is therefore an object of the invention to provide a system and method for producing viral particles, in particular HIV particles, which carry nucleotide constructs encoding inhibitory RNA molecules such as external guide sequences, optionally together with other classes of inhibitory RNA molecules such as ribozymes and/or antisense RNAs directed against a corresponding virus, such as HIV, within a target cell, that overcomes the above-mentioned problems. The system includes both a viral genome encoding the inhibitory RNA molecules and nucleotide constructs encoding the components required for packaging the viral genome in a producer cell. However, in contrast to the prior art, although the

packaging components have substantially the same amino acid sequence as the corresponding components of the target virus, the inhibitory RNA molecules do not affect production of the viral particles in the producer cells because the nucleotide sequence of the packaging components used in the viral system have been modified to prevent the inhibitory RNA molecules from effecting cleavage or degradation of the RNA transcripts produced from the constructs. Such a viral particle may be used to treat viral infections, in particular HIV infections.

Accordingly the present invention provides a viral vector system comprising:

(i) a first nucleotide sequence encoding an external guide sequence capable of binding to and effecting the cleavage by RNase P of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles; and

(ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that the third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by the external guide sequence.

Preferably, said system further comprises at least one further first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles, wherein the gene product is selected from an external guide sequence, a ribozyme and an anti-sense ribonucleic acid.

In another aspect, the present invention provides a viral vector production system comprising:

(i) a viral genome comprising at least one first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles;

(ii) a third nucleotide sequence encoding said viral polypeptide required for the

assembly of the viral genome into viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that said third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by said gene product;

- 5 wherein at least one of the gene products is an external guide sequence capable of binding to and effecting the cleavage by RNase P of the second nucleotide sequence.

Preferably, in addition to an external guide sequence, at least one gene product is selected from a ribozyme and an anti-sense ribonucleic acid, preferably a ribozyme.

10

Preferably, the viral vector is a retroviral vector, more preferably a lentiviral vector, such as an HIV vector. The second nucleotide sequence and the third nucleotide sequences are typically from the same viral species, more preferably from the same viral strain. Generally, the viral genome is also from the same viral species, more preferably from the

15

same viral strain.

In the case of retroviral vectors, the polypeptide required for the assembly of viral particles is selected from gag, pol and env proteins. Preferably at least the gag and pol sequences are lentiviral sequences, more preferably HIV sequences. Alternatively, or in addition, the

20

env sequence is a lentiviral sequence, more preferably an HIV sequence.

In a preferred embodiment, the third nucleotide sequence is resistant to cleavage directed by the gene product as a result of one or more conservative alterations in the nucleotide sequence which remove cleavage sites recognised by the at least one gene product and/or

25

binding sites for the at least one gene product. For example, where the gene product is an EGS, the third nucleotide sequence is adapted to prevent EGS binding and/or to remove the RNase P consensus cleavage site. Alternatively, where the gene product is a ribozyme, the third nucleotide sequence is adapted to be resistant to cleavage by the ribozyme.

30

Preferably the third nucleotide sequence is codon optimised for expression in host cells. The host cells, which term includes producer cells and packaging cells, are typically mammalian cells.



In a particularly preferred embodiment, (i) the viral genome is an HIV genome comprising nucleotide sequences encoding anti-HIV EGSs and optionally anti-HIV ribozyme sequences directed against HIV packaging component sequences (such as gag.pol) in a target HIV and (ii) the viral system for producing packaged HIV particles further comprises nucleotide constructs encoding the same packaging components (such as gag.pol proteins) as in the target HIV wherein the sequence of the nucleotide constructs is different from that found in the target HIV so that the anti-HIV EGS and anti-HIV ribozyme sequences cannot effect cleavage or degradation of the gag.pol transcripts during production of the HIV particles in producer cells.

The present invention also provides a viral particle comprising a viral vector according to the present invention and one or more polypeptides encoded by the third nucleotide sequences according to the present invention. For example the present invention provides a viral particle produced using the viral vector production system of the invention.

In another aspect, the present invention provides a method for producing a viral particle which method comprises introducing into a host cell (i) a viral genome vector according to the present invention; (ii) one or more third nucleotide sequences according to the present invention; and (iii) nucleotide sequences encoding the other essential viral packaging components not encoded by the one or more third nucleotide sequences.

The present invention further provides a viral particle produced using by the method of the invention.

The present invention also provides a pharmaceutical composition comprising a viral particle according to the present invention together with a pharmaceutically acceptable carrier or diluent.

The viral system of the invention or viral particles of the invention may be used to treat viral infections, particularly retroviral infections such as lentiviral infections including HIV infections. Thus the present invention provides a method of treating a viral infection which

method comprises administering to a human or animal patient suffering from the viral infection an effective amount of a viral system, viral particle or pharmaceutical composition of the present invention.

- 5 The invention relates in particular to HIV-based vectors carrying anti-HIV EGSs. However, the invention can be applied to any other virus, in particular any other lentivirus, for which treatment by gene therapy may be desirable. The invention is illustrated herein for HIV, but this is not considered to limit the scope of the invention to HIV-based anti-HIV vectors.

10

#### Detailed Description of the Invention

The term "viral vector" refers to a nucleotide construct comprising a viral genome capable of being transcribed in a host cell, which genome comprises sufficient viral genetic information to allow packaging of the viral RNA genome, in the presence of packaging components, into a viral particle capable of infecting a target cell. Infection of the target cell includes reverse transcription and integration into the target cell genome, where appropriate for particular viruses. The viral vector in use typically carries heterologous coding sequences (nucleotides of interest) which are to be delivered by the vector to the target cell, for example a first nucleotide sequence encoding an EGS. A viral vector is incapable of independent replication to produce infectious viral particles within the final target cell.

The term "viral vector system" is intended to mean a kit of parts which can be used when combined with other necessary components for viral particle production to produce viral particles in host cells. For example, the first nucleotide sequence may typically be present in a plasmid vector construct suitable for cloning the first nucleotide sequence into a viral genome vector construct. When combined in a kit with a third nucleotide sequence, which will also typically be present in a separate plasmid vector construct, the resulting combination of plasmid containing the first nucleotide sequence and plasmid containing the third nucleotide sequence comprises the essential elements of the invention. Such a kit may then be used by the skilled person in the production of suitable viral vector genome

constructs which when transfected into a host cell together with the plasmid containing the third nucleotide sequence, and optionally nucleic acid constructs encoding other components required for viral assembly, will lead to the production of infectious viral particles.

5

Alternatively, the third nucleotide sequence may be stably present within a packaging cell line that is included in the kit.

10

The kit may include the other components needed to produce viral particles, such as host cells and other plasmids encoding essential viral polypeptides required for viral assembly. By way of example, the kit may contain (i) a plasmid containing a first nucleotide sequence encoding an anti-HIV EGS and (ii) a plasmid containing a third nucleotide sequence encoding a modified HIV gag.pol construct which cannot be cleaved by the anti-HIV ribozyme. Optional components would then be (a) an HIV viral genome construct with suitable restriction enzyme recognition sites for cloning the first nucleotide sequence into the viral genome; (b) a plasmid encoding a VSV-G env protein. Alternatively, nucleotide sequence encoding viral polypeptides required for assembly of viral particles may be provided in the kit as packaging cell lines comprising the nucleotide sequences, for example a VSV-G expressing cell line.

15

20

The term "viral vector production system" refers to the viral vector system described above wherein the first nucleotide sequence has already been inserted into a suitable viral vector genome.

25

Viral vectors are typically retroviral vectors, in particular lentiviral vectors such as HIV vectors. The retroviral vector of the present invention may be derived from or may be derivable from any suitable retrovirus. A large number of different retroviruses have been identified. Examples include: murine leukemia virus (MLV), human immunodeficiency virus (HIV), simian immunodeficiency virus, human T-cell leukemia virus (HTLV), equine infectious anaemia virus (EIAV), mouse mammary tumour virus (MMTV), Rous sarcoma virus (RSV), Fujinami sarcoma virus (FuSV), Moloney murine leukemia virus (Mo-MLV), FBR murine osteosarcoma virus (FBR MSV), Moloney murine sarcoma virus

30

(Mo-MSV), Abelson murine leukemia virus (A-MLV), Avian myelocytomatosis virus-29 (MC29), and Avian erythroblastosis virus (AEV). A detailed list of retroviruses may be found in Coffin *et al.*, 1997, "Retroviruses", Cold Spring Harbour Laboratory Press Eds: JM Coffin, SM Hughes, HE Varmus pp 758-763.

5

Details on the genomic structure of some retroviruses may be found in the art. By way of example, details on HIV and Mo-MLV may be found from the NCBI Genbank (Genome Accession Nos. AF033819 and AF033811, respectively).

- 10 The lentivirus group can be split even further into "primate" and "non-primate". Examples of primate lentiviruses include human immunodeficiency virus (HIV), the causative agent of human auto-immunodeficiency syndrome (AIDS), and simian immunodeficiency virus (SIV). The non-primate lentiviral group includes the prototype "slow virus" visna/maedi virus (VMV), as well as the related caprine arthritis-encephalitis virus (CAEV), equine  
15 infectious anaemia virus (EIAV) and the more recently described feline immunodeficiency virus (FIV) and bovine immunodeficiency virus (BIV).

The basic structure of a retrovirus genome is a 5' LTR and a 3' LTR, between or within which are located a packaging signal to enable the genome to be packaged, a primer  
20 binding site, integration sites to enable integration into a host cell genome and *gag*, *pol* and *env* genes encoding the packaging components - these are polypeptides required for the assembly of viral particles. More complex retroviruses have additional features, such as *rev* and RRE sequences in HIV, which enable the efficient export of RNA transcripts of the integrated provirus from the nucleus to the cytoplasm of an infected target cell.

25

In the provirus, these genes are flanked at both ends by regions called long terminal repeats (LTRs). The LTRs are responsible for proviral integration, and transcription. LTRs also serve as enhancer-promoter sequences and can control the expression of the viral genes. Encapsidation of the retroviral RNAs occurs by virtue of a *psi* sequence located at the 5'  
30 end of the viral genome.

The LTRs themselves are identical sequences that can be divided into three elements, which are called U3, R and U5. U3 is derived from the sequence unique to the 3' end of the RNA. R is derived from a sequence repeated at both ends of the RNA and U5 is derived from the sequence unique to the 5' end of the RNA. The sizes of the three elements can vary considerably among different retroviruses.

In a defective retroviral vector genome *gag*, *pol* and *env* may be absent or not functional. The R regions at both ends of the RNA are repeated sequences. U5 and U3 represent unique sequences at the 5' and 3' ends of the RNA genome respectively.

In a typical retroviral vector for use in gene therapy, at least part of one or more of the *gag*, *pol* and *env* protein coding regions essential for replication may be removed from the virus. This makes the retroviral vector replication-defective. The removed portions may even be replaced by a nucleotide sequence of interest (NOI), such as a first nucleotide sequence of the invention, to generate a virus capable of integrating its genome into a host genome but wherein the modified viral genome is unable to propagate itself due to a lack of structural proteins. When integrated in the host genome, expression of the NOI occurs - resulting in, for example, a therapeutic and/or a diagnostic effect. Thus, the transfer of an NOI into a site of interest is typically achieved by: integrating the NOI into the recombinant viral vector; packaging the modified viral vector into a virion coat; and allowing transduction of a site of interest - such as a targeted cell or a targeted cell population.

A minimal retroviral genome for use in the present invention will therefore comprise (5') R - U5 - one or more first nucleotide sequences - U3-R (3'). However, the plasmid vector used to produce the retroviral genome within a host cell/packaging cell will also include transcriptional regulatory control sequences operably linked to the retroviral genome to direct transcription of the genome in a host cell/packaging cell. These regulatory sequences may be the natural sequences associated with the transcribed retroviral sequence, i.e. the 5' U3 region, or they may be a heterologous promoter such as another viral promoter, for example the CMV promoter.

Some retroviral genomes require additional sequences for efficient virus production. For example, in the case of HIV, *rev* and RRE sequence are preferably included. However the requirement for *rev* and RRE can be reduced or eliminated by codon optimisation.

5 Once the retroviral vector genome is integrated into the genome of its target cell as proviral DNA, the ribozyme sequences need to be expressed. In a retrovirus, the promoter is located in the 5' LTR U3 region of the provirus. In retroviral vectors, the promoter driving expression of a therapeutic gene may be the native retroviral promoter in the 5' U3 region, or an alternative promoter engineered into the vector. The alternative promoter may  
10 physically replace the 5' U3 promoter native to the retrovirus, or it may be incorporated at a different place within the vector genome such as between the LTRs.

Thus, the first nucleotide sequence will also be operably linked to a transcriptional regulatory control sequence to allow transcription of the first nucleotide sequence to occur  
15 in the target cell. The control sequence will typically be active in mammalian cells. The control sequence may, for example, be a viral promoter such as the natural viral promoter or a CMV promoter or it may be a mammalian promoter. It is particularly preferred to use a promoter that is preferentially active in a particular cell type or tissue type in which the virus to be treated primarily infects. Thus, in one embodiment, a tissue-specific regulatory  
20 sequences may be used. The regulatory control sequences driving expression of the one or more first nucleotide sequences may be constitutive or regulated promoters.

Replication-defective retroviral vectors are typically propagated, for example to prepare suitable titres of the retroviral vector for subsequent transduction, by using a combination  
25 of a packaging or helper cell line and the recombinant vector. That is to say, that the three packaging proteins can be provided *in trans*.

A "packaging cell line" contains one or more of the retroviral *gag*, *pol* and *env* genes. The packaging cell line produces the proteins required for packaging retroviral DNA but it  
30 cannot bring about encapsidation due to the lack of a *psi* region. However, when a recombinant vector carrying an NOI and a *psi* region is introduced into the packaging cell line, the helper proteins can package the *psi*-positive recombinant vector to produce the

recombinant virus stock. This virus stock can be used to transduce cells to introduce the NOI into the genome of the target cells. It is preferred to use a *psi* packaging signal, called *psi* plus, that contains additional sequences spanning from upstream of the splice donor to downstream of the *gag* start codon (Bender *et al.*, 1987) since this has been shown to  
5 increase viral titres.

The recombinant virus whose genome lacks all genes required to make viral proteins can transduce only once and cannot propagate. These viral vectors which are only capable of a single round of transduction of target cells are known as replication defective vectors.  
10 Hence, the NOI is introduced into the host/target cell genome without the generation of potentially harmful retrovirus. A summary of the available packaging lines is presented in Coffin *et al.*, 1997 (*ibid*).

Retroviral packaging cell lines in which the *gag*, *pol* and *env* viral coding regions are  
15 carried on separate expression plasmids that are independently transfected into a packaging cell line are preferably used. This strategy, sometimes referred to as the three plasmid transfection method (Soneoka *et al.*, 1995) reduces the potential for production of a replication-competent virus since three recombinant events are required for wild type viral production. As recombination is greatly facilitated by homology, reducing or eliminating  
20 homology between the genomes of the vector and the helper can also be used to reduce the problem of replication-competent helper virus production.

An alternative to stably transfected packaging cell lines is to use transiently transfected cell lines. Transient transfections may advantageously be used to measure levels of vector  
25 production when vectors are being developed. In this regard, transient transfection avoids the longer time required to generate stable vector-producing cell lines and may also be used if the vector or retroviral packaging components are toxic to cells. Components typically used to generate retroviral vectors include a plasmid encoding the *gag/pol* proteins, a plasmid encoding the *env* protein and a plasmid containing an NOI. Vector production  
30 involves transient transfection of one or more of these components into cells containing the other required components. If the vector encodes toxic genes or genes that interfere with the replication of the host cell, such as inhibitors of the cell cycle or genes that induce

apoptosis, it may be difficult to generate stable vector-producing cell lines, but transient transfection can be used to produce the vector before the cells die. Also, cell lines have been developed using transient transfection that produce vector titre levels that are comparable to the levels obtained from stable vector-producing cell lines (Pear *et al.*, 1993).

Producer cells/packaging cells can be of any suitable cell type. Most commonly, mammalian producer cells are used but other cells, such as insect cells are not excluded. Clearly, the producer cells will need to be capable of efficiently translating the *env* and *gag*, *pol* mRNA. Many suitable producer/packaging cell lines are known in the art. The skilled person is also capable of making suitable packaging cell lines by, for example stably introducing a nucleotide construct encoding a packaging component into a cell line.

As will be discussed below, where the retroviral genome encodes an inhibitory RNA molecule capable of effecting the cleavage of *gag*, *pol* and/or *env* RNA transcripts, the nucleotide sequences present in the packaging cell line, either integrated or carried on plasmids, or in the transiently transfected producer cell line, which encode *gag*, *pol* and or *env* proteins will be modified so as to reduce or prevent binding of the inhibitory RNA molecule(s). In this way, the inhibitory RNA molecule(s) will not prevent expression of components in packaging cell lines that are essential for packaging of viral particles.

It is highly desirable to use high-titre virus preparations in both experimental and practical applications. Techniques for increasing viral titre include using a *psi* plus packaging signal as discussed above and concentration of viral stocks. In addition, the use of different envelope proteins, such as the G protein from vesicular-stomatitis virus has improved titres following concentration to  $10^9$  per ml (Cosset *et al.*, 1995). However, typically the envelope protein will be chosen such that the viral particle will preferentially infect cells that are infected with the virus which it desired to treat. For example where an HIV vector is being used to treat HIV infection, the *env* protein used will be the HIV *env* protein.

Suitable first nucleotide sequences for use according to the present invention encode gene products that result in the cleavage and/or enzymatic degradation of a target nucleotide



sequence, which will generally be a ribonucleotide. As particular examples, EGSs, ribozymes, and antisense sequences may be mentioned, more specifically EGSs.

*External guide sequences* (EGSs) are RNA sequences that bind to a complementary target sequence to form a loop in the target RNA sequence, the overall structure being a substrate for RNaseP-mediated cleavage of the target RNA sequence. The structure that forms when the EGS anneals to the target RNA is very similar to that found in a tRNA precursor. The the natural activity of RNaseP can be directed to cleave a target RNA by designing a suitable EGS. The general rules for EGS design are as follows, with reference to the generic EGSs shown in Figure 9B:

Rules for EGS design in mammalian cells (see Figure 9B)

Target sequence - All tRNA precursor molecules have a G immediately 3' of the RNaseP cleavage site (i.e. the G forms a base pair with the C at the top of the acceptor stem prior to the ACCA sequence). In addition a U is found 8 nucleotides downstream in all tRNAs. (i.e. G at position 1, U at position 8). A pyrimidine may be preferred 5' of the cut site. No other specific target sequences are required.

EGS sequence - A 7 nucleotide 'acceptor stem' analogue is optimal (5' hybridising arm). A 4 nucleotide 'D-stem' analogue is preferred (3' hybridising arm). Variation in this length may alter the reaction kinetics. This will be specific to each target site. A consensus 'T-stem and loop' analogue is essential. Minimal 5' and 3' non-pairing sequences are preferred to reduce the potential for undesired folding of the EGS RNA.

Deletion of the 'anti-codon stem and loop' analogue may be beneficial. Deletion of the variable loop can also be tolerated *in vitro* but an optimal replacement loop for the deletion of both has not been defined *in vivo*.

As with ribozymes, described below, it is preferred to use more than one EGS. Preferably, a plurality of EGSs is employed, together capable of cleaving *gag*, *pol* and *env* RNA of the native retrovirus at a plurality of sites. Since HIV exists as a population of quasispecies,

not all of the target sequences for the EGSs will be included in all HIV variants. The problem presented by this variability can be overcome by using multiple EGs. Multiple EGSs can be included in series in a single vector and can function independently when expressed as a single RNA sequence. A single RNA containing two or more EGSs having different target recognition sites may be referred to as a multitarget EGS.

Further guidance may be obtained by reference to, for example, Werner *et al.* (1997); Werner *et al.* (1998); Ma *et al.* (1998) and Kawa *et al.* (1998).

*Ribozymes* are RNA enzymes which cleave RNA at specific sites. Ribozymes can be engineered so as to be specific for any chosen sequence containing a ribozyme cleavage site. Thus, ribozymes can be engineered which have chosen recognition sites in transcribed viral sequences. By way of an example, ribozymes encoded by the first nucleotide sequence recognise and cleave essential elements of viral genomes required for the production of viral particles, such as packaging components. Thus, for retroviral genomes, such essential elements include the *gag*, *pol* and *env* gene products. A suitable ribozyme capable of recognising at least one of the *gag*, *pol* and *env* gene sequences, or more typically, the RNA sequences transcribed from these genes, is able to bind to and cleave such a sequence. This will reduce or prevent production of the *gag*, *pol* or *env* protein as appropriate and thus reduce or prevent the production of retroviral particles.

Ribozymes come in several forms, including hammerhead, hairpin and hepatitis delta antigenomic ribozymes. Preferred for use herein are hammerhead ribozymes, in part because of their relatively small size, because the sequence requirements for their target cleavage site are minimal and because they have been well characterised. The ribozymes most commonly used in research at present are hammerhead and hairpin ribozymes.

Each individual ribozyme has a motif which recognises and binds to a recognition site in the target RNA. This motif takes the form of one or more "binding arms", generally two binding arms. The binding arms in hammerhead ribozymes are the flanking sequences Helix I and Helix III, which flank Helix II. These can be of variable length, usually between 6 to 10 nucleotides each, but can be shorter or longer. The length of the flanking

sequences can affect the rate of cleavage. For example, it has been found that reducing the total number of nucleotides in the flanking sequences from 20 to 12 can increase the turnover rate of the ribozyme cleaving a HIV sequence, by 10-fold (Goodchild *et al.*, 1991). A catalytic motif in the ribozyme Helix II in hammerhead ribozymes cleaves the target RNA at a site which is referred to as the cleavage site. Whether or not a ribozyme will cleave any given RNA is determined by the presence or absence of a recognition site for the ribozyme containing an appropriate cleavage site.

Each type of ribozyme recognises its own cleavage site. The hammerhead ribozyme cleavage site has the nucleotide base triplet GUX directly upstream where G is guanine, U is uracil and X is any nucleotide base. Hairpin ribozymes have a cleavage site of BCUGNYR, where B is any nucleotide base other than adenine, N is any nucleotide, Y is cytosine or thymine and R is guanine or adenine. Cleavage by hairpin ribozymes takes place between the G and the N in the cleavage site.

The nucleic acid sequences encoding the packaging components (the "third nucleotide sequences") may be resistant to the ribozyme or ribozymes because they lack any cleavage sites for the ribozyme or ribozymes. This prohibits enzymatic activity by the ribozyme or ribozymes and therefore there is no effective recognition site for the ribozyme or ribozymes. Alternatively or additionally, the potential recognition sites may be altered in the flanking sequences which form the part of the recognition site to which the ribozyme binds. This either eliminates binding of the ribozyme motif to the recognition site, or reduces binding capability enough to destabilise any ribozyme-target complex and thus reduce the specificity and catalytic activity of the ribozyme. Where the flanking sequences only are altered, they are preferably altered such that catalytic activity of the ribozyme at the altered target sequence is negligible and is effectively eliminated.

Preferably, a series of several anti-HIV ribozymes is employed in the invention. These can be any anti-HIV ribozymes but must include one or more which cleave the RNA that is required for the expression of *gag*, *pol* or *env*. Preferably, a plurality of ribozymes is employed, together capable of cleaving *gag*, *pol* and *env* RNA of the native retrovirus at a plurality of sites. Since HIV exists as a population of quasispecies, not all of the target

sequences for the ribozymes will be included in all HIV variants. The problem presented by this variability can be overcome by using multiple ribozymes. Multiple ribozymes can be included in series in a single vector and can function independently when expressed as a single RNA sequence. A single RNA containing two or more ribozymes having different target recognition sites may be referred to as a multitarget ribozyme. The placement of ribozymes in series has been demonstrated to enhance cleavage. The use of a plurality of ribozymes is not limited to treating HIV infection but may be used in relation to other viruses, retroviruses or otherwise.

*Antisense technology* is well known on the art. There are various mechanisms by which antisense sequences are believed to inhibit gene expression. One mechanism by which antisense sequences are believed to function is the recruitment of the cellular protein RNaseH to the target sequence/antisense construct heteroduplex which results in cleavage and degradation of the heteroduplex. Thus the antisense construct, by contrast to ribozymes, can be said to lead indirectly to cleavage/degradation of the target sequence. Thus according to the present invention, a first nucleotide sequence may encode an antisense RNA that binds to either a gene encoding an essential/packaging component or the RNA transcribed from said gene such that expression of the gene is inhibited, for example as a result of RNaseH degradation of a resulting heteroduplex. It is not necessary for the antisense construct to encode the entire complementary sequence of the gene encoding an essential/packaging component - a portion may suffice. The skilled person will easily be able to determine how to design a suitable antisense construct.

By contrast, the nucleic acid sequences encoding the essential/packaging components of the viral particles required for the assembly of viral particles in the host cells/producer cells/packaging cells (the third nucleotide sequences) are resistant to the inhibitory RNA molecules encoded by the first nucleotide sequence. For example in the case of ribozymes, resistance is typically by virtue of alterations in the sequences which eliminate the ribozyme recognition sites. At the same time, the amino acid coding sequence for the essential/packaging components is retained so that the viral components encoded by the sequences remain the same, or at least sufficiently similar that the function of the essential/packaging components is not compromised.

The term "viral polypeptide required for the assembly of viral particles" means a polypeptide normally encoded by the viral genome to be packaged into viral particles, in the absence of which the viral genome cannot be packaged. For example, in the context of retroviruses such polypeptides would include gag, pol and env. The terms "packaging component" and "essential component" are also included within this definition.

In the case of antisense sequences, the third nucleotide sequence differs from the second nucleotide sequence encoding the target viral packaging component antisense sequence to the extent that although the antisense sequence can bind to the second nucleotide sequence, or transcript thereof, the antisense sequence can not bind effectively to the third nucleotide sequence or RNA transcribed from therefrom. The changes between the second and third nucleotide sequences will typically be conservative changes, although a small number of amino acid changes may be tolerated provided that, as described above, the function of the essential/packaging components is not significantly impaired.

Preferably, in addition to eliminating the inhibitory RNA recognition sites, the alterations to the coding sequences for the viral components improve the sequences for codon usage in the mammalian cells or other cells which are to act as the producer cells for retroviral vector particle production. This improvement in codon usage is referred to as "codon optimisation". Many viruses, including HIV and other lentiviruses, use a large number of rare codons and by changing these to correspond to commonly used mammalian codons, increased expression of the packaging components in mammalian producer cells can be achieved. Codon usage tables are known in the art for mammalian cells, as well as for a variety of other organisms.

Thus preferably, the sequences encoding the packaging components are codon optimised. More preferably, the sequences are codon optimised in their entirety. Following codon optimisation, it is found that there are numerous sites in the wild type *gag*, *pol* and *env* sequences which can serve as inhibitory RNA recognition sites and which are no longer present in the sequences encoding the packaging components. In an alternative but less practical strategy, the sequences encoding the packaging components can be altered by

targeted conservative alterations so as to render them resistant to selected inhibitory RNAs capable of effecting the cleavage of the wild type sequences.

An additional advantage of codon optimising HIV packaging components is that this can increase gene expression. In particular, it can render *gag*, *pol* expression Rev independent so that *rev* and RRE need not be included in the genome (Haas *et al.*, 1996). Rev-independent vectors are therefore possible. This in turn enables the use of anti-*rev* or RRE factors in the retroviral vector.

As described above, the packaging components for a retroviral vector include expression products of *gag*, *pol* and *env* genes. In accordance with the present invention, *gag* and *pol* employed in the packaging system are derived from the target retrovirus on which the vector genome is based. Thus, in the RNA transcript form, *gag* and *pol* would normally be cleavable by the ribozymes present in the vector genome. The *env* gene employed in the packaging system may be derived from a different virus, including other retroviruses such as MLV and non-retroviruses such as VSV (a Rhabdovirus), in which case it may not need any sequence alteration to render it resistant to cleavage effected by the inhibitory RNA(s). Alternatively, *env* may be derived from the same retrovirus as *gag* and *pol*, in which case any recognition sites for the inhibitory RNA(s) will need to be eliminated by sequence alteration.

The process of producing a retroviral vector in which the envelope protein is not the native envelope of the retrovirus is known as "pseudotyping". Certain envelope proteins, such as MLV envelope protein and vesicular stomatitis virus G (VSV-G) protein, pseudotype retroviruses very well. Pseudotyping can be useful for altering the target cell range of the retrovirus. Alternatively, to maintain target cell specificity for target cells infected with the particular virus it is desired to treat, the envelope protein may be the same as that of the target virus, for example HIV.

Other therapeutic coding sequences may be present along with the first nucleotide sequence or sequences. Other therapeutic coding sequences include, but are not limited to, sequences encoding cytokines, hormones, antibodies, immunoglobulin fusion proteins,

enzymes, immune co-stimulatory molecules, anti-sense RNA, a transdominant negative mutant of a target protein, a toxin, a conditional toxin, an antigen, a single chain antibody, tumour suppresser protein and growth factors. When included, such coding sequences are operatively linked to a suitable promoter, which may be the promoter driving expression of the first nucleotide sequence or a different promoter or promoters.

Thus the invention comprises two components. The first is a genome construction that will be packaged by viral packaging components and which carries a series of anti-viral inhibitory RNA molecules such as anti-HIVEGs. These could be any anti-HIV EGSs but the key issue for this invention is that some of them result in cleavage of RNA that is required for the expression of native or wild type HIV *gag*, *pol* or *env* coding sequences. The second component is the packaging system which comprises a cassette for the expression of HIV *gag*, *pol* and a cassette either for HIV *env* or an envelope gene encoding a pseudotyping envelope protein - the packaging system being resistant to the inhibitory RNA molecules.

The viral particles of the present invention, and the viral vector system and methods used to produce may thus be used to treat or prevent viral infections, preferably retroviral infections, in particular lentiviral, especially HIV, infections. Specifically, the viral particles of the invention, typically produced using the viral vector system of the present invention may be used to deliver inhibitory RNA molecules to a human or animal in need of treatment for a viral infection.

Alternatively, or in addition, the viral production system may be used to transfect cells obtained from a patient *ex vivo* and then returned to the patient. Patient cells transfected *ex vivo* may be formulated as a pharmaceutical composition (see below) prior to readministration to the patient.

Preferably the viral particles are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Thus, the present invention also provides a pharmaceutical composition for treating an individual, wherein the composition comprises a therapeutically effective amount of the viral particle of the present invention,

together with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant. The pharmaceutical composition may be for human or animal usage.

5 The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s), and other carrier agents that may aid or increase the viral entry into  
10 the target site (such as for example a lipid delivery system).

The pharmaceutical composition may be formulated for parenteral, intramuscular, intravenous, intracranial, subcutaneous, intraocular or transdermal administration.

15 Where appropriate, the pharmaceutical compositions can be administered by any one or more of: inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or  
20 suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intracavernosally, intravenously, intramuscularly or subcutaneously. For parenteral administration, the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual  
25 administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

The amount of virus administered is typically in the range of from  $10^3$  to  $10^{10}$  pfu, preferably from  $10^5$  to  $10^8$  pfu, more preferably from  $10^6$  to  $10^7$  pfu. When injected,  
30 typically 1-10  $\mu$ l of virus in a pharmaceutically acceptable suitable carrier or diluent is administered.



When the polynucleotide/vector is administered as a naked nucleic acid, the amount of nucleic acid administered is typically in the range of from 1  $\mu$ g to 10 mg, preferably from 100  $\mu$ g to 1 mg.

5 Where the first nucleotide sequence (or other therapeutic sequence) is under the control of an inducible regulatory sequence, it may only be necessary to induce gene expression for the duration of the treatment. Once the condition has been treated, the inducer is removed and expression of the NOI is stopped. This will clearly have clinical advantages. Such a system may, for example, involve administering the antibiotic tetracycline, to activate gene  
10 expression via its effect on the tet repressor/VP16 fusion protein.

The invention will now be further described by way of Examples, which are meant to serve to assist one of ordinary skill in the art in carrying out the invention and are not intended in any way to limit the scope of the invention. The Examples refer to the Figures. In the  
15 Figures:

Figure 1 shows schematically ribozymes inserted into four different HIV vectors;

Figure 2 shows schematically how to create a suitable 3' LTR by PCR;

20

Figure 3 shows the codon usage table for wild type HIV *gag,pol* of strain HXB2 (accession number: K03455).

25

Figure 4 shows the codon usage table of the codon optimised sequence designated *gag,pol-SYNgp*.

Figure 5 shows the codon usage table of the wild type HIV *env* called *env-mn*.

30

Figure 6 shows the codon usage table of the codon optimised sequence of HIV *env* designated *SYNgp160mn*.

Figure 7 shows three plasmid constructs for use in the invention.

Figure 8 shows the principle behind two systems for producing retroviral vector particles.

Figure 9 A shows an EGS based on tyrosyl t-RNA

5

Figure 9B shows a consensus EGS sequence.

Figure 10 shows twelve different anti-HIV EGS constructs.

10 Figure 11 is a schematic representation of pDozenEgs and construction of pH4DozenEgs.

The invention will now be further described in the Examples which follow, which are intended as an illustration only and do not limit the scope of the invention.

## 15 EXAMPLES

### Reference Example 1 - Construction of a Ribozyme-encoding Genome

The HIV *gag.pol* sequence was codon optimised (Figure 4 and SEQ I.D. No. 1) and  
20 synthesised using overlapping oligos of around 40 nucleotides. This has three advantages. Firstly it allows an HIV based vector to carry ribozymes and other therapeutic factors. Secondly the codon optimisation generates a higher vector titre due to a higher level of gene expression. Thirdly *gag.pol* expression becomes *rev* independent which allows the use of anti-*rev* or RRE factors.

25

Conserved sequences within *gag.pol* were identified by reference to the HIV Sequence database at Los Alamos National Laboratory (<http://hiv-web.lanl.gov/>) and used to design ribozymes. Because of the variability between subtypes of HIV-1 the ribozymes were designed to cleave the predominant subtype within North America, Latin America and the  
30 Caribbean, Europe, Japan and Australia; that is subtype B. The sites chosen were cross-referenced with the synthetic *gagpol* sequence to ensure that there was a low possibility of cutting the codon optimised *gagpol* mRNA. The ribozymes were designed with *XhoI* and

*Sa*II sites at the 5' and 3' end respectively. This allows the construction of separate and tandem ribozymes.

- 5 The ribozymes are hammerhead (Riddell *et al.*, 1996) structures of the following general structure:

Helix I	Helix II	Helix III
5' - NNNNNNNN~	CUGAUGAGGCCGAAAGGCCGAA	~NNNNNNNN~

10

The catalytic domain of the ribozyme (Helix II) can tolerate some changes without reducing catalytic turnover.

- 15 The cleavage sites, targeting *gag* and *pol*, with the essential GUX triplet (where X is any nucleotide base) are as follows:

GAG 1	5'	UAGUAAGAAUGUAUAGCCCUAC
GAG 2	5'	AACCCAGAUUGUAAGACUAUUU
GAG 3	5'	UGUUUCAAUUGUGGCAAAGAAG
20 GAG 4	5'	AAAAAGGGCUGUUGGAAAUGUG
POL 1	5'	ACGACCCCUCGUCACAAUAAAG
POL 2	5'	GGAAUUGGAGGUUUUAUCAAAG
POL 3	5'	AUAUUUUUCAGUCCCCUAGAU
POL 4	5'	UGGAUGAUUUGUAUGUAGGAUC
25 POL 5	5'	CUUUGGAUGGGUUAUGAACUCC
POL 6	5'	CAGCUGGACUGUCAUGACAUA
POL 7	5'	AACUUUCUAUGUAGAUGGGGCA
POL 8	5'	AAGGCCGCCUGUUGGUGGGCAG
POL 9	5'	UAAGACAGCAGUACAAAUGGCA

30

The ribozymes are inserted into four different HIV vectors (pH4 (Gervais *et al.*, 1997), pH6, pH4.1, or pH6.1) (Figure 1). In pH4 and pH6, transcription of the ribozymes is

driven by an internal HCMV promoter (Foecking *et al.*, 1986). From pH4.1 and pH6.1, the ribozymes are expressed from the 5' LTR. The major difference between pH4 and pH6 (and pH4.1 and pH6.1) resides in the 3' LTR in the production plasmid. pH4 and pH4.1 have the HIV U3 in the 3' LTR. pH6 and pH6.1 have HCMV in the 3'LTR. The HCMV promoter replaces most of the U3 and will drive expression at high constitutive levels while the HIV-1 U3 will support a high level of expression only in the presence of Tat.

The HCMV/HIV-1 hybrid 3' LTR is created by recombinant PCR with three PCR primers (Figure 2). The first round of PCR is performed with RIB1 and RIB2 using pH4 (Kim *et al.*, 1998) as the template to amplify the HIV-1 HXB2 sequence 8900-9123. The second round of PCR makes the junction between the 5' end of the HIV-1 U3 and the HCMV promoter by amplifying the hybrid 5' LTR from pH4. The PCR product from the first PCR reaction and RIB3 serves as the 5' primer and 3' primer respectively.

RIB1: 5' - CAGCTGCTCGAGCAGCTGAAGCTTGCATGC - 3'

RIB2: 5' - GTAAGTTATGTAACGGACGATATCTTGTCTTCTT - 3'

RIB3: 5' - CGCATAGTCGACGGGCCCCGCCACTGCTAGAGATTTTC - 3'

The PCR product is then cut with *SphI* and *SalI* and inserted into pH4 thereby replacing the 3' LTR. The resulting plasmid is designated pH6. To construct pH4.1 and pH6.1, the internal HCMV promoter (*SpeI* - *XhoI*) in pH4 and pH6 is replaced with the polycloning site of pBluescript II KS+ (Stratagene) (*SpeI* - *XhoI*).

The ribozymes are inserted into the *XhoI* sites in the genome vector backbones. Any ribozymes in any configuration could be used in a similar way.

## Reference Example 2 - Construction of a Packaging System

The packaging system can take various forms. In a first form of packaging system, the HIV gag, pol components are co-expressed with the HIV env coding sequence. In this case, both the gag, pol and the env coding sequences are altered such that they are resistant to the anti-HIV ribozymes that are built into the genome. At the same time as altering the

codon usage to achieve resistance, the codons can be chosen to match the usage pattern of the most highly expressed mammalian genes. This dramatically increases expression levels and so increases titre. A codon optimised HIV env coding sequence has been described by Haas *et al.* (1996). In the present example, a modified codon optimised HIV  
5 env sequence is used (SEQ I.D. No. 3). The corresponding env expression plasmid is designated pSYNgp160mn. The modified sequence contains extra motifs not used by Haas *et al.* The extra sequences were taken from the HIV env sequence of strain MN and codon optimised. Any similar modification of the nucleic acid sequence would function similarly as long as it used codons corresponding to abundant tRNAs (Zolotukhin *et al.*, 1996) and  
10 lead to resistance to the ribozymes in the genome.

In one example of a gag, pol coding sequence with optimised codon usage, overlapping oligonucleotides are synthesised and then ligated together to produce the synthetic coding sequence. The sequence of a wild-type (Genbank accession no. K03455) and synthetic  
15 (gagpol-SYNgp) gagpol sequence is shown in SEQ I.D. Nos 1 and 2, respectively and their codon usage is shown in Figures 3 and 4, respectively. The sequence of a wild type env coding sequence (Genbank Accession No. M17449) is given in SEQ I.D. No 3, the sequence of a synthetic codon optimised sequence is given in SEQ. I.D. No. 4 and their codon usage tables are given in Figures 5 and 6, respectively. As with the env coding  
20 sequence any gag, pol sequence that achieves resistance to the ribozymes could be used. The synthetic sequence shown is designated gag, pol-SYNgp and has an *EcoRI* site at the 5' end and a *NotI* site at the 3' end. It is inserted into pCneo (Promega) to produce plasmid pSYNgp.

25 In a second form of the packaging system a synthetic gag, pol cassette is coexpressed with a non-HIV envelope coding sequence that produces a surface protein that pseudotypes HIV. This could be for example VSV-G (Ory *et al.*, 1996; Zhu *et al.*, 1990), amphotropic MLV env (Chesebro *et al.*, 1990; Spector *et al.*, 1990) or any other protein that would be incorporated into the HIV particle (Valesia-Wittman, 1994). This includes molecules  
30 capable of targeting the vector to specific tissues. Coding sequences for non-HIV envelope proteins not cleaved by the ribozymes and so no sequence modification is required

(although some sequence modification may be desirable for other reasons such as optimisation for codon usage in mammalian cells).

### Reference Example 3 - Vector Particle Production

5

Vector particles can be produced either from a transient three-plasmid transfection system similar to that described by Soneoka *et al.* (1995) or from producer cell lines similar to those used for other retroviral vectors (Ory *et al.*, 1996; Srinivasakumar *et al.*, 1997; Yu *et al.*, 1996). These principles are illustrated in Figures 7 and 8. For example, by using  
10 pH6Rz, pSYNgp and pRV67 (VSV-G expression plasmid) in a three plasmid transfection of 293T cells (Figure 8), as described by Soneoka *et al.* (1995), vector particles designated H6Rz-VSV are produced. These transduce the H6Rz genome to CD4+ cells such as C1866 or Jurkat and produce the multitarget ribozymes. HIV replication in these cells is now severely restricted.

15

### Example 1 - Use of external guide sequences for inhibiting HIV

Ribonuclease P is an nuclear localised enzyme consisting of protein and RNA subunits. It has been found in all organisms examined and is one of the most abundant, stable and  
20 efficient enzymes in cells. Its enzymatic activity is responsible for the maturation of the 5' termini of all tRNAs which account for about 2% of the total cellular RNA.

For tRNA processing, it has been shown that RNase P recognises a secondary structure of the tRNA. However extensive studies have shown that any complex of two RNA  
25 molecules which resemble the one tRNA molecule will also be recognised and cleaved by RNase P. Consequently the natural activity of RNase P can and has been successfully re-directed to target other RNA species (see Yaun and Altman, 1994, and references therein). This is achieved by engineering a sequence, containing the flanking motif recognised by RNaseP, to bind the desired target sequence. These sequences are called external guide  
30 sequence (EGSs).

Outlined here is a strategy employing the EGS system against HIV RNA. Shown in Figure 2 A, B and C are twelve EGS sequences designed to target twelve separate HIV gag/pol sequences. These target sequences are conserved throughout the clade B of HIV. The sequence numbering in each figure designates the position of the required conserved G of each target sequences based on the HXB2 published sequence.

The external guide sequences shown here all have anticodon stem-loops deleted. These are non-limiting examples; for instance full length 3/4 tRNA based EGSs might be used if preferred (see Yuan and Altman, 1994).

Outlined in SEQ ID. Nos. 5 to 10 (see below) and Figure 11 is the cloning strategy employed to construct an HIV vector containing the EGSs described in SEQ ID. Nos. 5 to 10. The oligonucleotides prefixed 1, 2, 3, 4, 5 and 6 are respectively annealed together and sequentially cloned into the pSP72 (Promega) cloning vector starting with the oligo. duplex 1/1A being cloned into the *XhoI*-*SalI* site such that the EGS 4762 and EGS 4715 are orientated away from the ampicillin gene. The remaining oligonucleotides (with *XhoI* ends) are subsequently cloned stepwise (starting with oligo. duplex 2/2A, ending with duplex 6/6A) into the unique *SalI* site (present within the terminus of the each preceding oligonucleotide) to create the plasmid pDOZENEGS. The EGSs from this vector are then transferred by *XhoI*-*SphI* digest into the pH4Z similarly cut such that the multiple EGSs cassette replaces the lacZ gene of pH4Z (Kim *et al.*, 1998). The resulting vector is named pH4DOZENEGS (see SEQ ID. No. 11 for complete sequence).

#### Egs 1/1A (SEQ ID. No. 5)

*XhoI*

5' - tcgagcccggggatgacgtcatcgacttcgaaggttcgaatccttctactgccaccatttttt  
cgggcccctactgcagtagctgaagcttccaagcttaggaagatgacgggtggtaaaaaa  
ctctacgtcatcgacttcgaaggttcgaatccttccctgtccaccagtcgacc-3'  
gagatgcagtagctgaagcttccaagcttaggaagggacaggtggtcagctggagct-5'

#### Egs 2/2A (SEQ ID. No. 6)

5' - tcgagtattacgtcatcgacttcgaaggttcgaatccttctagattcaccatttttttaggaacg  
cataatgcagtagctgaagcttccaagcttaggaagtactaagtggtaaaaaatccttgc

tcatcgacttcgaaggttcgaatccttccagttccaccagtcgacc-3'  
agtagctgaagcttccaagcttaggaaggtcaaggtggtcagctggagct-5'

Egs 3/3A (SEQ ID. No. 7)

5

5' - tcgaggccaacgtcatcgacttcgaaggttcgaatccttcttcccaccatttttttcc  
ccggttgtagctgaagcttccaagcttaggaagagaaggggtggtaaaaaaaagg

acgtcatcgacttcgaaggttcgaatccttcggggcccaccagtcgacc-3'  
tgcagtagctgaagcttccaagcttaggaagccccgggtggtcagctggagct-5'

10

Egs 4/4A (SEQ ID. No. 8)

5' - tcgagggctacgtcatcgacttcgaaggttcgaatccttcttcttcaccatttttt  
cccgatgcagtagctgaagcttccaagcttaggaagaacgaagtggtaaaaaa

15

ctgaacgtcatcgacttcgaaggttcgaatccttctgctgtcaccagtcgacc-3'  
gacttgtagctgaagcttccaagcttaggaagacgacagtggtcagctggagct-5'

Egs 5/5A (SEQ ID. No. 9)

20

5' - tcgagtataacgtcatcgacttcgaaggttcgaatccttcaccgggtcaccatttttttata  
catattgcagtagctgaagcttccaagcttaggaagtggccagtggtaaaaaaatat

acgtcatcgacttcgaaggttcgaatccttcttcttacaccagtcgacc-3'  
tgcagtagctgaagcttccaagcttaggaagaagaatgtggtcagctggagct-5'

25

Egs 6/6A (SEQ ID. No. 10)

5' - tcgaggtacacgtcatcgacttcgaaggttcgaatccttcgtagttcaccattttttgtgc  
ccatgtgcagtagctgaagcttccaagcttaggaagcatcaagtggtaaaaaacacg

SphI

30

acgtcatcgacttcgaaggttcgaatccttcttagggcccaccagtcgacgcatgcc-3'  
tgcagtagctgaagcttccaagcttaggaagatccgggtggtcagctgcgtacggagct-5'

The pH4DOZENEGS<sub>2</sub> vector may be used to both deliver and express the example EGS sequences to appropriate eukaryotic cells in a manner as described for ribozymes in reference examples 1, 2 and 3 whereby the use of a codon optimised gag/pol and env genes would prevent EGSs from targeting these genes during viral production. The inclusion of the EGS sequences into an HIV derived vector will not only allow expression of such sequences in the target cell but also packaging and transfer of such therapeutic sequences by the patient's own HIV. These example EGS sequences target HIV RNA for cleavage by RNase P. This example is not limiting and other suitable EGS and derived sequences

40



may also be used; be they expressed singularly, in multiples, from pol I, pol II or pol III promoters and derivatives thereof and/or in combination with other HIV treatments. Other appropriate nucleotide sequences of interest (NOIs) may also be included in combination with EGSs if preferred.

5

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred  
10 embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

15 References

- Bender *et al.*, 1987, J Virol 61: 1639-1646.  
Chesebro, B., K. Wehrly, and W. Maury. 1990. J Virol. 64:4553-7.  
Cosset *et al.*, 1995, J. Virol. 69: 7430-7436.  
20 Foecking, M. K., and H. Hofstetter. 1986. Gene. 45:101-105.  
Forster and Altman, 1990, Science 249: 783-786.  
Gervaix, A., X. Li, G. Kraus, and F. Wong Staal. 199. J Virol. 71 :3048-53.  
Goodchild, J., V. Kohli. 1991. *Arch Biochem Biophys* Feb 1; 284(2):386-391.  
Haas, J., E.-C. Park, and B. Seed. 1996. Current Biology. 6:315.  
25 Kawa *et al.*, 1998, RNA 4: 1397-1406.  
Kim, V. N., K. Mitrophanous, S. M. Kingsman, and K. A. J. 1998. J Virol 72: 811-816.  
Lever, A. M. 1995. Br Med Bull. 51:149-66.  
Ma *et al.*, 1998, Antisense and Nucleic Acid Drug Development 8: 415-426.  
Ory, D. S., B. A. Neugeboren, and R. C. Mulligan. 1996. Proc Natl Acad Sci U S A.  
30 93:11400-6.  
Pear *et al.*, 1993, Proc Natl Acad Sci 90: 8392-8396.  
Riddell, S. R., M. Elliott, D. A. Lewinsohn, M. J. Gilbert, L. Wilson, S. A. Manley, S. D.

- Lupton, R. W. Overell, T. C. Reynolds, L. Corey, and P. D. Greenberg. 1996. *Nat Med.* 2:216-23.
- Soneoka, Y., P. M. Cannon, E. E. Ramsdale, J. C. Griffiths, G. Romano, S. M. Kingsman, and A. J. Kingsman. 1995. *Nucleic Acids Res.* 23:628-33.
- 5 Spector, D. H., E. Wade, D. A. Wright, V. Koval, C. Clark, D. Jaquish, and S. A. Spector. 1990. *J Virol.* 64:2298-2308.
- Srinivasakumar, N., N. Chazal, C. Helga Maria, S. Prasad, M. L. Hammarskjold, and D. Rekosh. 1997. *J Virol.* 71 :5841-8.
- Valsesia Wittmann, S., A. Drynda, G. Deleage, M. Aumailley, J. M. Heard, O. Danos, G. 10 Verdier, and F. L. Cosset. 1994. *J Virol.* 68:4609-19.
- Werner *et al.*, 1997, *Nucleic Acids Symposium Series No. 36*: 19-21.
- Werner *et al.*, 1998, *RNA* 4: 847-855.
- Yu, H., A. B. Rabson, M. Kaul, Y. Ron, and J. P. Dougherty. 1996. *J Virol.* 70:4530-37.
- Yuan and Altman, 1994, *Science* 263:1269-1273.
- 15 Yuan and Altman, 1995, *EMBO J.* 14: 159-168.
- Yuan *et al.*, 1992, *Proc Natl Acad Sci* 89: 8006-8010.
- Zhu, Z. H., S. S. Chen, and A. S. Huang. 1990. *J Acquir Immune Defic Syndr.* 3:215-9.
- Zolotukhin, S., M. Potter, W. W. Hauswirth, J. Guy, and N. Muzyczka. 1996. *J Virol.* 70:4646-54.

SEQUENCE LISTING PART OF THE DESCRIPTION

SEQ. ID. NO. 1 - Wild type gagpol sequence for strain HXB2 (accession no. K03455)

ATGGGTGCGA	GAGCGTCAGT	ATTAAGCGGG	GGAGAATTAG	ATCGATGGGA	AAAAATTCGG	60
TTAAGGCCAG	GGGGAAAGAA	AAAATATAAA	TTAAAACATA	TAGTATGGGC	AAGCAGGGAG	120
CTAGAACGAT	TCGCAGTTAA	TCCTGGCCTG	TTAGAAACAT	CAGAAGGCTG	TAGACAAATA	180
CTGGGACAGC	TACAACCATC	CCTTCAGACA	GGATCAGAAG	AACTTAGATC	ATTATATAAT	240
ACAGTAGCAA	CCCTCTATTG	TGTGCATCAA	AGGATAGAGA	TAAAAGACAC	CAAGGAAGCT	300
TTAGACAAGA	TAGAGGAAGA	GCAAAACAAA	AGTAAGAAAA	AAGCACAGCA	AGCAGCAGCT	360
GACACAGGAC	ACAGCAATCA	GGTCAGCCAA	AATTACCCTA	TAGTGCAGAA	CATCCAGGGG	420
CAAATGGTAC	ATCAGGCCAT	ATCACCTAGA	ACTTTAAATG	CATGGGTAAA	AGTAGTAGAA	480
GAGAAGGCTT	TCAGCCCAGA	AGTGATACCC	ATGTTTTTCAG	CATTATCAGA	AGGAGCCACC	540
CCACAAGATT	TAAACACCAT	GCTAAACACA	GTGGGGGGAC	ATCAAGCAGC	CATGCAAATG	600
TTAAAAGAGA	CCATCAATGA	GGAAGCTGCA	GAATGGGATA	GAGTGCATCC	AGTGCATGCA	660
GGGCCTATTG	CACCAGGCCA	GATGAGAGAA	CCAAGGGGAA	GTGACATAGC	AGGAACTACT	720
AGTACCCTTC	AGGAACAAAT	AGGATGGATG	ACAAATAATC	CACCTATCCC	AGTAGGAGAA	780
ATTTATAAAA	GATGGATAAT	CCTGGGATTA	AATAAAATAG	TAAGAATGTA	TAGCCCTACC	840
AGCATTCTGG	ACATAAGACA	AGGACCAAAG	GAACCCTTTA	GAGACTATGT	AGACCGGTTT	900
TATAAACTC	TAAGAGCCGA	GCAAGCTTCA	CAGGAGGTAA	AAAATTGGAT	GACAGAAACC	960
TTGTTGGTCC	AAAATGCGAA	CCCAGATTGT	AAGACTATTT	TAAAAGCATT	GGGACCAGCG	1020
GCTACACTAG	AAGAAATGAT	GACAGCATGT	CAGGGAGTAG	GAGGACCCGG	CCATAAGGCA	1080
AGAGTTTTGG	CTGAAGCAAT	GAGCCAAGTA	ACAAATTCAG	CTACCATAAT	GATGCAGAGA	1140
GGCAATTTTA	GGAACCAAAG	AAAGATTGTT	AAGTGTTC	ATTGTGGCAA	AGAAGGGCAC	1200
ACAGCCAGAA	ATTGCAGGGC	CCCTAGGAAA	AAGGGCTGTT	GGAAATGTGG	AAAGGAAGGA	1260
CACCAAATGA	AAGATTGTAC	TGAGAGACAG	GCTAATTTTT	TAGGGAAGAT	CTGGCCTTCC	1320
TACAAGGGAA	GGCCAGGGAA	TTTTCTTCAG	AGCAGACCAG	AGCCAACAGC	CCCACCAGAA	1380
GAGAGCTTCA	GGTCTGGGGT	AGAGACAACA	ACTCCCCCTC	AGAAGCAGGA	GCCGATAGAC	1440
AAGGAAGTGT	ATCCTTTAAC	TTCCCTCAGG	TCACTCTTTG	GCAACGACCC	CTCGTCACAA	1500
TAAAGATAGG	GGGGCAACTA	AAGGAAGCTC	TATTAGATAC	AGGAGCAGAT	GATACAGTAT	1560
TAGAAGAAAT	GAGTTTGCCA	GGAAGATGGA	AACCAAAAAT	GATAGGGGGA	ATTGGAGGTT	1620
TTATCAAAGT	AAGACAGTAT	GATCAGATAC	TCATAGAAAT	CTGTGGACAT	AAAGCTATAG	1680
GTACAGTATT	AGTAGGACCT	ACACCTGTCA	ACATAATTGG	AAGAAATCTG	TTGACTCAGA	1740
TTGGTTGCAC	TTTAAATTTT	CCCATTAGCC	CTATTGAGAC	TGTACCAGTA	AAATTTAAAGC	1800
CAGGAATGGA	TGGCCCCAAA	GTAAACAAT	GGCCATTGAC	AGAAGAAAAA	ATAAAAGCAT	1860
TAGTAGAAAT	TTGTACAGAG	ATGGAAAAGG	AAGGGAAAAT	TTCAAAAATT	GGGCCTGAAA	1920
ATCCATACAA	TACTCCAGTA	TTTGCCATAA	AGAAAAAAGA	CAGTACTAAA	TGGAGAAAAT	1980
TAGTAGATTT	CAGAGAACTT	AATAAGAGAA	CTCAAGACTT	CTGGGAAGTT	CAATTAGGAA	2040
TACCACATCC	CGCAGGGTTA	AAAAAGAAAA	AATCAGTAAC	AGTACTGGAT	GTGGGTGATG	2100
CATATTTTTT	AGTTCCCTTA	GATGAAGACT	TCAGGAAGTA	TACTGCATTT	ACCATACCTA	2160
GTATAACAA	TGAGACACCA	GGGATTAGAT	ATCAGTACAA	TGTGCTTCCA	CAGGGATGGA	2220
AAGGATCACC	AGCAATATTC	CAAAGTAGCA	TGACAAAAAT	CTTAGAGCCT	TTTAGAAAAC	2280
AAAATCCAGA	CATAGTTATC	TATCAATACA	TGGATGATTT	GTATGTAGGA	TCTGACTTAG	2340
AAATAGGGCA	GCATAGAACA	AAAATAGAGG	AGCTGAGACA	ACATCTGTTG	AGGTGGGGAC	2400
TTACCACACC	AGACAAAAAA	CATCAGAAAG	AACCTCCATT	CCTTTGGATG	GGTTATGAAC	2460
TCCATCCTGA	TAAATGGACA	GTACAGCCTA	TAGTGCTGCC	AGAAAAAGAC	AGCTGGACTG	2520
TCAATGACAT	ACAGAAGTTA	GTGGGGAAAT	TGAATTGGGC	AAGTCAGATT	TACCCAGGGA	2580

TTAAAGTAAG	GCAATTATGT	AAACTCCTTA	GAGGAACCAA	AGCACTAACA	GAAGTAATAC	2640
CACTAACAGA	AGAAGCAGAG	CTAGAAGTGG	CAGAAAACAG	AGAGATTCTA	AAAGAACCAG	2700
TACATGGAGT	GTATTATGAC	CCATCAAAAG	ACTTAATAGC	AGAAATACAG	AAGCAGGGGC	2760
AAGGCCAATG	GACATATCAA	ATTTATCAAG	AGCCATTTAA	AAATCTGAAA	ACAGGAAAAT	2820
ATGCAAGAAT	GAGGGGTGCC	CACACTAATG	ATGTAAAAACA	ATTAACAGAG	GCAGTGCAAA	2880
AAATAACCCAC	AGAAAGCATA	GTAATATGGG	GAAAGACTCC	TAAATTTAAA	CTGCCCATAC	2940
AAAAGGAAAC	ATGGGAAACA	TGGTGGACAG	AGTATTGGCA	AGCCACCTGG	ATTCCTGAGT	3000
GGGAGTTTGT	TAATACCCCT	CCCTTAGTGA	AATTATGGTA	CCAGTTAGAG	AAAGAACCCA	3060
TAGTAGGAGC	AGAAACCTTC	TATGTAGATG	GGGCAGCTAA	CAGGGAGACT	AAATTAGGAA	3120
AAGCAGGATA	TGTTACTAAT	AGAGGAAGAC	AAAAAGTTGT	CACCTAACT	GACACAACAA	3180
ATCAGAAGAC	TGAGTTACAA	GCAATTTATC	TAGCTTTGCA	GGATTCGGGA	TTAGAAGTAA	3240
ACATAGTAAC	AGACTCACAA	TATGCATTAG	GAATCATTCA	AGCACAACCA	GATCAAAGTG	3300
AATCAGAGTT	AGTCAATCAA	ATAATAGAGC	AGTTAATAAA	AAAGGAAAAG	GTCTATCTGG	3360
CATGGGTACC	AGCACACAAA	GGAATTGGAG	GAAATGAACA	AGTAGATAAA	TTAGTCAGTG	3420
CTGGAATCAG	GAAAGTACTA	TTTTTAGATG	GAATAGATAA	GGCCCAAGAT	GAACATGAGA	3480
AATATCACAG	TAATTGGAGA	GCAATGGCTA	GTGATTTTAA	CCTGCCACCT	GTAGTAGCAA	3540
AAGAAATAGT	AGCCAGCTGT	GATAAATGTC	AGCTAAAAGG	AGAAGCCATG	CATGGACAAG	3600
TAGACTGTAG	TCCAGGAATA	TGGCAACTAG	ATTGTACACA	TTTAGAAGGA	AAAGTTATCC	3660
TGGTAGCAGT	TCATGTAGCC	AGTGGATATA	TAGAAGCAGA	AGTTATTCCA	GCAGAAACAG	3720
GGCAGGAAAC	AGCATATTTT	CTTTTAAAT	TAGCAGGAAG	ATGGCCAGTA	AAAACAATAC	3780
ATACTGACAA	TGGCAGCAAT	TTCACCGGTG	CTACGGTTAG	GGCCGCCTGT	TGGTGGGCGG	3840
GAATCAAGCA	GGAATTTGGA	ATTCCTTACA	ATCCCCAAAG	TCAAGGAGTA	GTAGAATCTA	3900
TGAATAAAGA	ATTAAAGAAA	ATTATAGGAC	AGGTAAGAGA	TCAGGCTGAA	CATCTTAAGA	3960
CAGCAGTACA	AATGGCAGTA	TTCATCCACA	ATTTTAAAAG	AAAAGGGGGG	ATTGGGGGGT	4020
ACAGTGACAG	GGAAAGAATA	GTAGACATAA	TAGCAACAGA	CATACAACT	AAAGAATTAC	4080
AAAAACAAAT	TACAAAAATT	CAAAATTTTC	GGGTTTATTA	CAGGGACAGC	AGAAATTCAC	4140
TTTGGAAGG	ACCAGCAAAG	CTCCTCTGGA	AAGGTGAAGG	GGCAGTAGTA	ATACAAGATA	4200
ATAGTGACAT	AAAAGTAGTG	CCAAGAAGAA	AAGCAAAGAT	CATTAGGGAT	TATGGAAAAC	4260
AGATGGCAGG	TGATGATTGT	GTGGCAAGTA	GACAGGATGA	GGATTAG		4307

# SEQ I.D. NO. 2 - gagpol-SYNgp - codon optimised gagpol sequence

ATGGGCGCCC	GCGCCAGCGT	GCTGTCGGGC	GGCGAGCTGG	ACCGCTGGGA	GAAGATCCGC	60
CTGCGCCCCG	GCGGCAAAAA	GAAGTACAAG	CTGAAGCACA	TCGTGTGGGC	CAGCCGCGAA	120
CTGGAGCGCT	TCGCCGTGAA	CCCCGGGCTC	CTGGAGACCA	GCGAGGGGTG	CCGCCAGATC	180
CTCGGCCAAC	TGCAGCCAG	CCTGCAAACC	GGCAGCGAGG	AGCTGCGCAG	CCTGTACAAC	240
ACCGTGGCCA	CGCTGTACTG	CGTCCACCAG	CGCATCGAAA	TCAAGGATAC	GAAAGAGGCC	300
CTGGATAAAA	TCGAAGAGGA	ACAGAATAAG	AGCAAAAAGA	AGGCCCAACA	GGCCGCCGCG	360
GACACCGGAC	ACAGCAACCA	GGTCAGCCAG	AACTACCCCA	TCGTGCAGAA	CATCCAGGGG	420
CAGATGGTGC	ACCAGGCCAT	CTCCCCCGC	ACGCTGAACG	CCTGGGTGAA	GGTGGTGGAA	480
GAGAAGGCTT	TTAGCCCGGA	GGTGATACCC	ATGTTCTCAG	CCCTGTCAGA	GGGAGCCACC	540
CCCCAAGATC	TGAACACCAT	GCTCAACACA	GTGGGGGGAC	ACCAGGCCGC	CATGCAGATG	600
CTGAAGGAGA	CCATCAATGA	GGAGGCTGCC	GAATGGGATC	GTGTGCATCC	GGTGCACGCA	660
GGGCCCATCG	CACCGGGCCA	GATGCGTGAG	CCACGGGGCT	CAGACATCGC	CGGAACGACT	720
AGTACCCTTC	AGGAACAGAT	CGGCTGGATG	ACCAACAACC	CACCCATCCC	GGTGGGAGAA	780
ATCTACAAAC	GCTGGATCAT	CCTGGGCCTG	AACAAGATCG	TGCGCATGTA	TAGCCCTACC	840
AGCATCCTGG	ACATCCGCCA	AGGCCCGAAG	GAACCCTTTC	GCGACTACGT	GGACCGGTTC	900

TACAAAACGC	TCCGCGCCGA	GCAGGCTAGC	CAGGAGGTGA	AGAACTGGAT	GACCGAAACC	960
CTGCTGGTCC	AGAACGCGAA	CCCGGACTGC	AAGACGATCC	TGAAGGCCCT	GGGCCCAGCG	1020
GCTACCCTAG	AGGAAATGAT	GACCGCCTGT	CAGGGAGTGG	GCGGACCCGG	CCACAAGGCA	1080
CGCGTCCTGG	CTGAGGCCAT	GAGCCAGGTG	ACCAACTCCG	CTACCATCAT	GATGCAGCGC	1140
GGCAACTTTC	GGAACCAACG	CAAGATCGTC	AAGTGCTTCA	ACTGTGGCAA	AGAAGGGCAC	1200
ACAGCCCACA	ACTGCAGGGC	CCCTAGGAAA	AAGGGCTGCT	GGAAATGCGG	CAAGGAAGGC	1260
CACCAGATGA	AAGACTGTAC	TGAGAGACAG	GCTAATTTTT	TAGGGAAGAT	CTGGCCTTCC	1320
TACAAGGGAA	GGCCAGGGAA	TTTTCTTCAG	AGCAGACCAG	AGCCAACAGC	CCCACCAGAA	1380
GAGAGCTTCA	GGTCTGGGGT	AGAGACAACA	ACTCCCCCTC	AGAAGCAGGA	GCCGATAGAC	1440
AAGGAACTGT	ATCCTTTAAC	TTCCCTCAGA	TCACTCTTTG	GCAACGACCC	CTCGTCACAA	1500
TAAAGATAGG	GGGGCAGCTC	AAGGAGGCTC	TCCTGGACAC	CGGAGCAGAC	GACACCGTGC	1560
TGGAGGAGAT	GTCGTTGCCA	GGCCGCTGGA	AGCCGAAGAT	GATCGGGGGA	ATCGGCGGTT	1620
TCATCAAGGT	GCGCCAGTAT	GACCAGATCC	TCATCGAAAT	CTGCGGCCAC	AAGGCTATCG	1680
GTACCGTGCT	GGTGGGCCCC	ACACCCGTCA	ACATCATCGG	ACGCAACCTG	TTGACGCAGA	1740
TCGGTTGCAC	GCTGAACTTC	CCCATTAGCC	CTATCGAGAC	GGTACCGGTG	AAGCTGAAGC	1800
CCGGGATGGA	CGGCCCAGAG	GTCAAGCAAT	GGCCATTGAC	AGAGGAGAAG	ATCAAGGCAC	1860
TGGTGGAGAT	TTGCACAGAG	ATGGAAAAGG	AAGGGAAAAAT	CTCCAAGATT	GGGCCTGAGA	1920
ACCCGTACAA	CACGCCGGTG	TTCGCAATCA	AGAAGAAGGA	CTCGACGAAA	TGGCGCAAGC	1980
TGGTGGACTT	CCGCGAGCTG	AACAAGCGCA	CGCAAGACTT	CTGGGAGGTT	CAGCTGGGCA	2040
TCCCGCACCC	CGCAGGGCTG	AAGAAGAAGA	AATCCGTGAC	CGTACTGGAT	GTGGGTGATG	2100
CCTACTTCTC	CGTTCCCCTG	GACGAAGACT	TCAGGAAGTA	CACTGCCTTC	ACAATCCCTT	2160
CGATCAACAA	CGAGACACCG	GGGATTGATG	ATCAGTACAA	CGTGCTGCCC	CAGGGCTGGA	2220
AAGGCTCTCC	CGCAATCTTC	CAGAGTAGCA	TGACCAAAAT	CCTGGAGCCT	TTCCGCAAAAC	2280
AGAACCCCGA	CATCGTCATC	TATCAGTACA	TGGATGACTT	GTACGTGGGC	TCTGATCTAG	2340
AGATAGGGCA	GCACCGCACC	AAGATCGAGG	AGCTGCGCCA	GCACCTGTTG	AGGTGGGGAC	2400
TGACCACACC	CGACAAGAAG	CACCAGAAGG	AGCCTCCCTT	CCTCTGGATG	GGTTACGAGC	2460
TGCACCCTGA	CAAATGGACC	GTGCAGCCTA	TCGTGCTGCC	AGAGAAAGAC	AGCTGGACTG	2520
TCAACGACAT	ACAGAAGCTG	GTGGGGAAGT	TGAACTGGGC	CAGTCAGATT	TACCCAGGGA	2580
TTAAGGTGAG	GCAGCTGTGC	AAACTCCTCC	GCGGAACCAA	GGCACTCACA	GAGGTGATCC	2640
CCCTAACCGA	GGAGGCCGAG	CTCGAACTGG	CAGAAAACCG	AGAGATCCTA	AAGGAGCCCCG	2700
TGCACGGCGT	GTACTATGAC	CCCTCCAAGG	ACCTGATCGC	CGAGATCCAG	AAGCAGGGGC	2760
AAGGCCAGTG	GACCTATCAG	ATTTACCAGG	AGCCCTTCAA	GAACCTGAAG	ACCGGCAAGT	2820
ACGCCCCGAT	GAGGGGTGCC	CACACTAACG	ACGTCAAGCA	GCTGACCGAG	GCCGTGCAGA	2880
AGATCACCAC	CGAAAGCATC	GTGATCTGGG	GAAAGACTCC	TAAGTTCAAG	CTGCCCATCC	2940
AGAAGGAAAC	CTGGGAAACC	TGGTGGACAG	AGTATTGGCA	GGCCACCTGG	ATTCTGAGT	3000
GGGAGTTCGT	CAACACCCCT	CCCCTGGTGA	AGCTGTGGTA	CCAGCTGGAG	AAGGAGCCCA	3060
TAGTGGGCGC	CGAAACCTTC	TACGTGGATG	GGGCCGCTAA	CAGGGAGACT	AAGCTGGGCA	3120
AAGCCGGATA	CGTACTAAC	CGGGGCAGAC	AGAAGGTTGT	CACCCTCACT	GACACCACCA	3180
ACCAGAAGAC	TGAGCTGCAG	GCCATTTACC	TCGCTTTGCA	GGACTCGGGC	CTGGAGGTGA	3240
ACATCGTGAC	AGACTCTCAG	TATGCCCTGG	GCATCATTCA	AGCCCAGCCA	GACCAGAGTG	3300
AGTCCGAGCT	GGTCAATCAG	ATCATCGAGC	AGCTGATCAA	GAAGGAAAAG	GTCTATCTGG	3360
CCTGGGTACC	CGCCACAAA	GGCATTGGCG	GCAATGAGCA	GGTCGACAAG	CTGGTCTCGG	3420
CTGGCATCAG	GAAGGTGCTA	TTCTGGATG	GCATCGACAA	GGCCCAGGAC	GAGCACGAGA	3480
AATACCACAG	CAACTGGCGG	GCCATGGCTA	GCGACTTCAA	CCTGCCCCCT	GTGGTGGCCA	3540
AAGAGATCGT	GGCCAGCTGT	GACAAGTGTC	AGCTCAAGGG	CGAAGCCATG	CATGGCCAGG	3600
TGGACTGTAG	CCCCGGCATC	TGGCAACTCG	ATTGCACCCA	TCTGGAGGGC	AAGGTTATCC	3660
TGGTAGCCGT	CCATGTGGCC	AGTGGCTACA	TCGAGGCCGA	GGTCATTCCC	GCCGAAACAG	3720
GGCAGGAGAC	AGCCTACTTC	CTCCTGAAGC	TGGCAGGCCG	GTGGCCAGTG	AAGACCATCC	3780

ATACTGACAA TGGCAGCAAT TTCACCAGTG CTACGGTTAA GGCCGCCTGC TGGTGGGCGG 3840  
 GAATCAAGCA GGAGTTCGGG ATCCCCTACA ATCCCAGAG TCAGGGCGTC GTCGAGTCTA 3900  
 TGAATAAGGA GTTAAAGAAG ATTATCGGCC AGGTCAGAGA TCAGGCTGAG CATCTCAAGA 3960  
 CCGCGGTCCA AATGGCGGTA TTCATCCACA ATTTCAAGCG GAAGGGGGGG ATTGGGGGGT 4020  
 ACAGTGCGGG GGAGCGGATC GTGGACATCA TCGCGACCGA CATCCAGACT AAGGAGCTGC 4080  
 AAAAGCAGAT TACCAAGATT CAGAATTTCC GGGTCTACTA CAGGGACAGC AGAAATCCCC 4140  
 TCTGGAAAGG CCCAGCGAAG CTCCTCTGGA AGGGTGAGGG GGCAGTAGTG ATCCAGGATA 4200  
 ATAGCGACAT CAAGGTGGTG CCCAGAAGAA AGGCGAAGAT CATTAGGGAT TATGGCAAAC 4260  
 AGATGGCGGG TGATGATTGC GTGGCGAGCA GACAGGATGA GGATTAG 4307

SEQ. ID. NO. 3 - Envelope Gene from HIV-1 MN (Genbank accession no. M17449)

ATGAGAGTGA AGGGGATCAG GAGGAATTAT CAGCACTGGT GGGGATGGGG CACGATGCTC 60  
 CTTGGGTAT TAATGATCTG TAGTGCTACA GAAAAATTGT GGGTCACAGT CTATTATGGG 120  
 GTACCTGTGT GGAAAGAAGC AACCACCACT CTATTTTGTG CATCAGATGC TAAAGCATAT 180  
 GATACAGAGG TACATAATGT TTGGGCCACA CAAGCCTGTG TACCCACAGA CCCCAACCCA 240  
 CAAGAAGTAG AATTGGTAAA TGTGACAGAA AATTTTAACA TGTGGAAAAA TAACATGGTA 300  
 GAACAGATGC ATGAGGATAT AATCAGTTTA TGGGATCAAA GCCTAAAGCC ATGTGTAAAA 360  
 TTAACCCAC TCTGTGTTAC TTTAAATTGC ACTGATTGTA GGAATACTAC TAATACCAAT 420  
 AATAGTACTG CTAATAACAA TAGTAATAGC GAGGGAACAA TAAAGGGAGG AGAAATGAAA 480  
 AACTGCTCTT TCAATATCAC CACAAGCATA AGAGATAAGA TGCAGAAAGA ATATGCACTT 540  
 CTTTATAAAC TTGATATAGT ATCAATAGAT AATGATAGTA CCAGCTATAG GTTGATAAGT 600  
 TGTAATACCT CAGTCATTAC ACAAGCTTGT CCAAAGATAT CCTTTGAGCC AATTCCCATA 660  
 CACTATTGTG CCCC GGCTGG TTTT GCGATT CTAAAATGTA ACGATAAAAA GTTCAGTGGA 720  
 AAAGGATCAT GTAAAAATGT CAGCACAGTA CAATGTACAC ATGGAATTAG GCCAGTAGTA 780  
 TCAACTCAAC TGCTGTTAAA TGGCAGTCTA GCAGAAGAAG AGGTAGTAAT TAGATCTGAG 840  
 AATTTCACTG ATAATGCTAA AACCATCATA GTACATCTGA ATGAATCTGT ACAAATTAAT 900  
 TGTACAAGAC CCAACTACAA TAAAAGAAAA AGGATACATA TAGGACCAGG GAGAGCATTT 960  
 TATACAACAA AAAATATAAT AGGAACTATA AGACAAGCAC ATTGTAACAT TAGTAGAGCA 1020  
 AAATGGAATG ACACTTTAAG ACAGATAGTT AGCAAATTAA AAGAACAATT TAAGAATAAA 1080  
 ACAATAGTCT TTAATCAATC CTCAGGAGGG GACCCAGAAA TTGTAATGCA CAGTTTTAAT 1140  
 TGTGGAGGGG AATTTTCTA CTGTAATACA TCACCACTGT TTAATAGTAC TTGGAATGGT 1200  
 AATAATACTT GGAATAATAC TACAGGGTCA AATAACAATA TCACACTTCA ATGCAAAATA 1260  
 AAACAAATTA TAAACATGTG GCAGGAAGTA GGAAAAGCAA TGTATGCCCC TCCCATTGAA 1320  
 GGACAAATTA GATGTTTCATC AAATATTACA GGGCTACTAT TAACAAGAGA TGGTGGTAAG 1380  
 GACACGGACA CGAACGACAC CGAGATCTTC AGACCTGGAG GAGGAGATAT GAGGGACAAT 1440  
 TGGAGAAGTG AATTATATAA ATATAAGTA GTAACAATTG AACCATTAGG AGTAGCACCC 1500  
 ACCAAGGCAA AGAGAAGAGT GGTGCAGAGA GAAAAAAGAG CAGCGATAGG AGCTCTGTTC 1560  
 CTTGGGTCT TAGGAGCAGC AGGAAGCACT ATGGGCGCAG CGTCAGTGAC GCTGACGGTA 1620  
 CAGGCCAGAC TATTATTGTC TGGTATAGTG CAACAGCAGA ACAATTTGCT GAGGGCCATT 1680  
 GAGGCGCAAC AGCATATGTT GCAACTCACA GTCTGGGGCA TCAAGCAGCT CCAGGCAAGA 1740  
 GTCCTGGCTG TGGAAAGATA CCTAAAGGAT CAACAGCTCC TGGGGTTTTG GGGTTGCTCT 1800  
 GGAAAACTCA TTTGCACCAC TACTGTGCTT TGGAAATGCTA GTTGGAGTAA TAAATCTCTG 1860  
 GATGATATTT GGAATAACAT GACCTGGATG CAGTGGGAAA GAGAAATTGA CAATTACACA 1920  
 AGCTTAATAT ACTCATTACT AGAAAAATCG CAAACCCAAC AAGAAAAGAA TGAACAAGAA 1980  
 TTATTGGAAT TGGATAAATG GGCAAGTTTG TGGAAATGGT TTGACATAAC AAATTGGCTG 2040  
 TGGTATATAA AAATATTCAT AATGATAGTA GGAGGCTTGG TAGGTTTAAG AATAGTTTTT 2100

GCTGTACTTT	CTATAGTGAA	TAGAGTTAGG	CAGGGATACT	CACCATTGTC	GTTGCAGACC	2160
CGCCCCCAG	TTCCGAGGGG	ACCCGACAGG	CCCGAAGGAA	TCGAAGAAGA	AGGTGGAGAG	2220
AGAGACAGAG	ACACATCCGG	TCGATTAGTG	CATGGATTCT	TAGCAATTAT	CTGGGTCGAC	2280
CTGCGGAGCC	TGTTCTCTT	CAGCTACCAC	CACAGAGACT	TACTCTTGAT	TGCAGCGAGG	2340
ATTGTGGAAC	TTCTGGGACG	CAGGGGGTGG	GAAGTCCTCA	AATATTGGTG	GAATCTCCTA	2400
CAGTATTGGA	GTCAGGAACT	AAAGAGTAGT	GCTGTTAGCT	TGCTTAATGC	CACAGCTATA	2460
GCAGTAGCTG	AGGGGACAGA	TAGGGTTATA	GAAGTACTGC	AAAGAGCTGG	TAGAGCTATT	2520
CTCCACATAC	CTACAAGAAT	AAGACAGGGC	TTGGAAAGGG	CTTTGCTATA	A	2571

SEQ. I.D. NO. 4 - SYNgp-160mn - codon optimised env sequence

ATGAGGGTGA	AGGGGATCCG	CCGCAACTAC	CAGCACTGGT	GGGGCTGGGG	CACGATGCTC	60
CTGGGGCTGC	TGATGATCTG	CAGCGCCACC	GAGAAGCTGT	GGGTGACCGT	GTACTACGGC	120
GTGCCCCGTG	GGAAGGAGGC	CACCACCACC	CTGTTCTGCG	CCAGCGACGC	CAAGGCGTAC	180
GACACCGAGG	TGCACAACGT	GTGGGGCCACC	CAGGCGTGCG	TGCCCACCGA	CCCCAACCCC	240
CAGGAGGTGG	AGCTCGTGAA	CGTGACCGAG	AACTTCAACA	TGTGGAAGAA	CAACATGGTG	300
GAGCAGATGC	ATGAGGACAT	CATCAGCCTG	TGGGACCAGA	GCCTGAAGCC	CTGCGTGAAG	360
CTGACCCCCC	TGTGCGTGAC	CCTGAACTGC	ACCGACCTGA	GGAACACCAC	CAACACCAAC	420
AACAGCACCG	CCAACAACAA	CAGCAACAGC	GAGGGCACCA	TCAAGGGCGG	CGAGATGAAG	480
AACTGCAGCT	TCAACATCAC	CACCAGCATC	CGCGACAAGA	TGCAGAAGGA	GTACGCCCTG	540
CTGTACAAGC	TGGATATCGT	GAGCATCGAC	AACGACAGCA	CCAGCTACCG	CCTGATCTCC	600
TGCAACACCA	GCCTGATCAC	CCAGGCCCTGC	CCCAAGATCA	GCTTCGAGCC	CATCCCCATC	660
CACTACTGCG	CCCCCGCCGG	CTTCGCCATC	CTGAAGTGCA	ACGACAAGAA	GTTTCAGCGGC	720
AAGGGCAGCT	GCAAGAACGT	GAGCACCGTG	CAGTGCACCC	ACGGCATCCG	GCCGGTGGTG	780
AGCACCCAGC	TCCTGCTGAA	CGGCAGCCTG	GCCGAGGAGG	AGGTGGTGAT	CCGCAGCGAG	840
AACTTCACCG	ACAACGCCAA	GACCATCATC	GTGCACCTGA	ATGAGAGCGT	GCAGATCAAC	900
TGCACGCGTC	CCAATAACAA	CAAGCGCAAG	CGCATCCACA	TCGGCCCCCG	GCGCGCCTTC	960
TACACCACCA	AGAACATCAT	CGGCACCATC	CGCCAGGCCC	ACTGCAACAT	CTCTAGAGCC	1020
AAGTGGAAAC	ACACCCTGCG	CCAGATCGTG	AGCAAGCTGA	AGGAGCAGTT	CAAGAACAAG	1080
ACCATCGTGT	TCAACCAGAG	CAGCGGCGGC	GACCCCGAGA	TCGTGATGCA	CAGCTTCAAC	1140
TGCGGCGGCG	AATTCTTCTA	CTGCAACACC	AGCCCCCTGT	TCAACAGCAC	CTGGAACGGC	1200
AACAACACCT	GGAACAACAC	CACCGGCAGC	AACAACAATA	TTACCCTCCA	GTGCAAGATC	1260
AAGCAGATCA	TCAACATGTG	GCAGGAGGTG	GGCAAGGCCA	TGTACGCCCC	CCCCATCGAG	1320
GGCCAGATCC	GGTGCAGCAG	CAACATCACC	GGTCTGCTGC	TGACCCGCGA	CGGCGGCAAG	1380
GACACCGACA	CCAACGACAC	CGAAATCTTC	CGCCCCGGCG	GCGGCGACAT	GCGCGACAAC	1440
TGGAGATCTG	AGCTGTACAA	GTACAAGGTG	GTGACGATCG	AGCCCCTGGG	CGTGGCCCCC	1500
ACCAAGGCCA	AGCGCCGCGT	GGTGCAGCGC	GAGAAGCGGG	CCGCCATCGG	CGCCCTGTTC	1560
CTGGGCTTCC	TGGGGGCGGC	GGGCAGCACC	ATGGGGGCGG	CCAGCGTGAC	CCTGACCGTG	1620
CAGGCCCGCC	TGCTCCTGAG	CGGCATCGTG	CAGCAGCAGA	ACAACCTCCT	CCGCGCCATC	1680
GAGGCCAGC	AGCATATGCT	CCAGCTCACC	GTGTGGGGCA	TCAAGCAGCT	CCAGGCCCGC	1740
GTGCTGGCCG	TGGAGCGCTA	CCTGAAGGAC	CAGCAGCTCC	TGGGCTTCTG	GGGCTGCTCC	1800
GGCAAGCTGA	TCTGCACCAC	CACGGTACCC	TGGAACGCCT	CCTGGAGCAA	CAAGAGCCTG	1860
GACGACATCT	GGAACAACAT	GACCTGGATG	CAGTGGGAGC	GCGAGATCGA	TAACATACAC	1920
AGCCTGATCT	ACAGCCTGCT	GGAGAAGAGC	CAGACCCAGC	AGGAGAAGAA	CGAGCAGGAG	1980
CTGCTGGAGC	TGGACAAGTG	GGCGAGCCTG	TGGAACCTGGT	TCGACATCAC	CAACTGGCTG	2040
TGGTACATCA	AAATCTTCAT	CATGATTGTG	GGCGGCCTGG	TGGGCCTCCG	CATCGTGTTC	2100
GCCGTGCTGA	GCATCGTGAA	CCGCGTGCGC	CAGGGCTACA	GCCCCCTGAG	CCTCCAGACC	2160

CGGCCCCCGG	TGCCGCGCGG	GCCCGACCGC	CCCAGGGGCA	TCGAGGAGGA	GGGCGGCGAG	2220
CGCGACCGCG	ACACCAGCGG	CAGGCTCGTG	CACGGCTTCC	TGGCGATCAT	CTGGGTGCGAC	2280
CTCCGCAGCC	TGTTCTGT	CAGCTACCAC	CACCGCGACC	TGCTGCTGAT	CGCCGCCCCG	2340
ATCGTGGAAC	TCCTAGGCCG	CCGCGGCTGG	GAGGTGCTGA	AGTACTGGTG	GAACCTCCTC	2400
CAGTATTGGA	GCCAGGAGCT	GAAGTCCAGC	GCCGTGAGCC	TGCTGAACGC	CACCGCCATC	2460
GCCGTGGCCG	AGGGCACCGA	CCGCGTGATC	GAGGTGCTCC	AGAGGGCCGG	GAGGGCGATC	2520
CTGCACATCC	CCACCCGCAT	CCGCCAGGGG	CTCAGAGGGG	CGCTGCTGTA	A	2571

# SEQ. I.D. NO. 11 - Complete Sequence of pH4DOZENEGS

CTGACGCGCC	CTGTAGCGGC	GCATTAAGCG	CGGCGGGTGT	GGTGGTTACG	CGCAGCGTGA	60
CCGCTACACT	TGCCAGCGCC	CTAGCGCCCCG	CTCCTTTCGC	TTTCTTCCCT	TCCTTTCTCG	120
CCACGTTCGC	CGGCTTTCCC	CGTCAAGCTC	TAAATCGGGG	GCTCCCTTTA	GGGTTCGGAT	180
TTAGTGCTTT	ACGGCACCTC	GACCCCAAAA	AACCTGATTA	GGGTGATGGT	TCACGTAGTG	240
GGCCATCGCC	CTGATAGACG	GTTTTTCGCC	CTTTGACGTT	GGAGTCCACG	TTCTTTAATA	300
GTGGACTCTT	GTTCCAAACT	GGAACAACAC	TCAACCCTAT	CTCGGTCTAT	TCTTTTGATT	360
TATAAGGGAT	TTTGCCGATT	TCGGCCTATT	GGTTAAAAAA	TGAGCTGATT	TAACAAAAAT	420
TTAACGCGAA	TTTTAACAAA	ATATTAACGC	TTACAATTTT	CATTCGCCAT	TCAGGCTGCG	480
CAACTGTTGG	GAAGGGCGAT	CGGTGCGGGC	CTCTTCGCTA	TTACGCCAGC	TGGCGAAAGG	540
GGGATGTGCT	GCAAGGCGAT	TAAGTTGGGT	AACGCCAGGG	TTTTCCAGT	CACGACGTTG	600
TAAAACGACG	GCCAGTGAGC	GCGCGTAATA	CGACTCACTA	TAGGGCGAAT	TGGAGCTCCA	660
CCGCGGTGGC	GGCCGCTCTA	GAGTCCGTTA	CATAACTTAC	GGTAAATGGC	CCGCCTGGCT	720
GACCGCCCAA	CGACCCCGCG	CCATTGACGT	CAATAATGAC	GTATGTTCCC	ATAGTAACGC	780
CAATAGGGAC	TTTCCATTGA	CGTCAATGGG	TGGAGTATTT	ACGGTAAACT	GCCCACCTTG	840
CAGTACATCA	AGTGTATCAT	ATGCCAAGTA	CGCCCCCTAT	TGACGTCAAT	GACGGTAAAT	900
GGCCCGCCTG	GCATTATGCC	CAGTACATGA	CCTTATGGGA	CTTTCCTACT	TGGCAGTACA	960
TCTACGTATT	AGTCATCGCT	ATTACCATGG	TGATGCGGTT	TTGGCAGTAC	ATCAATGGGC	1020
GTGGATAGCG	GTTTGACTCA	CGGGGATTTT	CAAGTCTCCA	CCCCATTGAC	GTCAATGGGA	1080
GTTTGTTTTG	GCACCAAAT	CAACGGGACT	TTCCAAAATG	TCGTAACAAC	TCCGCCCAT	1140
TGACGCAAAT	GGGCGGTAGG	CGTGTACGGT	GGGAGGTCTA	TATAAGCAGA	GCTCGTTTAG	1200
TGAACCGGTC	TCTCTGGTTA	GACCAGATCT	GAGCCTGGGA	GCTCTCTGGC	TAAGTAGGGA	1260
ACCCACTGCT	TAAGCCTCAA	TAAAGCTTGC	CTTGAGTGCT	TCAAGTAGTG	TGTGCCCGTC	1320
TGTTGTGTGA	CTCTGGTAAC	TAGAGATCCC	TCAGACCCTT	TTAGTCAGTG	TGGAAAATCT	1380
CTAGCAGTGG	CGCCCGAACA	GGGACTTGAA	AGCGAAAGGG	AAACCAGAGG	AGCTCTCTCG	1440
ACGCAGGACT	CGGCTTGCTG	AAGCGCGCAC	GGCAAGAGGC	GAGGGGCGGC	GACTGGTGAG	1500
TACGCCAAAA	ATTTTGACTA	GCGGAGGCTA	GAAGGAGAGA	GATGGGTGCG	AGAGCGTCAG	1560
TATTAAGCGG	GGGAGAATTA	GATCGCGATG	GGAAAAAATT	CGGTTAAGGC	CAGGGGGAAA	1620
GAAAAAATAT	AAATTAAGAA	ATATAGTATG	GGCAAGCAGG	GAGCTAGAAC	GATTGCGAGT	1680
TAATCCTGGC	CTGTTAGAAA	CATCAGAAGG	CTGTAGACAA	ATACTGGGAC	AGCTACAACC	1740
ATCCCTTCAG	ACAGGATCAG	AAGAACTTAG	ATCATTATAT	AATACAGTAG	CAACCCTCTA	1800
TTGTGTGCAT	CAAAGGTTGA	GATAAAAGAC	ACCAAGGAAG	CTTTAGACAA	GATAGAGGGA	1860
GAGCAAAACA	AAAGTAAGAA	AAAAGCACAG	CAAGCAGCAG	CTGACACAGG	ACACAGCAAT	1920
CAGGTCAGCC	AAAATTACCC	TATAGTGCAG	AACATCCAGG	GGCAAATGGT	ACATCAGGCC	1980
ATATCACCTA	GAACTTTAAA	TGCATGGGTA	AAAGTAGTAG	AAGAGAAGGC	TTTCAGCCCA	2040
GAAGTGATAC	CCATGTTTTT	AGCATTATCA	GAAGGAGCCA	CCCCACAAGA	TTTAAACACC	2100
ATGCTAAACA	CAGTGGGGGG	ACATCAAGCA	GCCATGCAAA	TGTTAAAAGA	GACCATCAAT	2160



GAGGAAGCTG	CAGGAATTCG	CCTAAAACTG	CTTGTACCAA	TTGCTATTGT	AAAAAGTGTT	2220
GCTTTTCATTG	CCAAGTTTGT	TTCATAACAA	AAGCCTTAGG	CATCTCCTAT	GGCAGGAAGA	2280
AGCGGAGACA	GCGACGAAGA	GCTCATCAGA	ACAGTCAGAC	TCATCAAGCT	TCTCTATCAA	2340
AGCAGTAAGT	AGTACATGTA	ACGCAACCTA	TACCAATAGT	AGCAATAGTA	GCATTAGTAG	2400
TAGCAATAAT	AATAGCAATA	GTTGTGTGGT	CCATAGTAAT	CATAGAATAT	AGGAAAATAT	2460
TAAGACAAAG	AAAAATAGAC	AGGTTAATTG	ATAGACTAAT	AGAAAGAGCA	GAAGACAGTG	2520
GCAATGAGAG	TGAAGGAGAA	ATATCAGCAC	TTGTGGAGAT	GGGGGTGGAG	ATGGGGCACC	2580
ATGCTCCTTG	GGATGTTGAT	GATCTGTAGT	GCTACAGAAA	AATTGTGGGT	CACAGTCTAT	2640
TATGGGGTAC	CTGTGTGGAA	GGAAGCAACC	ACCACTCTAT	TTTGTGCATC	AGATGCTAAA	2700
GCATAGATCT	TCAGACTTGG	AGGAGGAGAT	ATGAGGGACA	ATTGGAGAAG	TGAATTATAT	2760
AAATATAAAG	TAGTAAAAAT	TGAACCATTA	GGAGTAGCAC	CCACCAAGGC	AAAGAGAAGA	2820
GTGGTGCAGA	GAGAAAAAAG	AGCAGTGGGA	ATAGGAGCTT	TGTTCCCTTG	GTTCTTGGGA	2880
GCAGCAGGAA	GCACTATGGG	CGCAGCGTCA	ATGACGCTGA	CGGTACAGGC	CAGACAATTA	2940
TTGTCTGGTA	TAGTGCAGCA	GCAGAACAAT	TTGCTGAGGG	CTATTGAGGC	GCAACAGCAT	3000
CTGTTGCAAC	TCACAGTCTG	GGGCATCAAG	CAGCTCCAGG	CAAGAATCCT	GGCTGTGGAA	3060
AGATACCTAA	AGGATCAACA	GCTCCTGGGG	ATTTGGGGTT	GCTCTGGAAA	ACTCATTTGC	3120
ACCACTGCTG	TGCCTTGGAA	TGCTAGTTGG	AGTAATAAAT	CTCTGGAACA	GATCTGGAAT	3180
CACACGACCT	GGATGGAGTG	GGACAGAGAA	ATTAACAATT	ACACAAGCTT	AATACACTCC	3240
TTAATTGAAG	AATCGCAAAA	CCAGCAAGAA	AAGAATGAAC	AAGAATTATT	GGAATTAGAT	3300
AAATGGGCAA	GTTTGTGGAA	TTGGTTTAAC	ATAACAAATT	GGCTGTGGTA	TATAAAATTA	3360
TTCATAATGA	TAGTAGGAGG	CTTGGTAGGT	TTAAGAATAG	TTTTTGCTGT	ACTTTCTATA	3420
GTGAATAGAG	TTAGGCAGGG	ATATTCACCA	TTATCGTTTC	AGACCCACCT	CCCAACCCCG	3480
AGGGGACCCG	ACAGGCCCGA	AGGAATAGAA	GAAGAAGGTG	GAGAGAGAGA	CAGAGACAGA	3540
TCCATTCGAT	TAGTGAACGG	ATCCTTGGCA	CTTATCTGGG	ACGATCTGCG	GAGCCTGTGC	3600
CTCTTCAGCT	ACCACCGCTT	GAGAGACTTA	CTCTTGATTG	TAACGAGGAT	TGTGGAACCT	3660
CTGGGACGCA	GGGGGTGGGA	AGCCCTCAAA	TATTGGTGGA	ATCTCCTACA	GTATTGGAGT	3720
CAGGAACTAA	AGAATAGTGC	TGTTAGCTTG	CTCAATGCCA	CAGCCATAGC	AGTAGCTGAG	3780
GGGACAGATA	GGGTTATAGA	AGTAGTACAA	GGAGCTTGTA	GAGCTATTCT	CCACATACCT	3840
AGAAGAATAA	GACAGGGCTT	GGAAAGGATT	TTGCTATAAG	ATGGGTGGCA	AGTGGTCAAA	3900
AAGTAGTGTG	ATTGGATGGC	CTACTGTAAG	GGAAAGAATG	AGACGAGCTG	AGCCAGCAGC	3960
AGATAGGGTG	GGAGCAGCAT	CTCGACGCTG	CAGGAGTGGG	GAGGCACGAT	GGCCGCTTTG	4020
GTCGAGGCGG	ATCCGGCCAT	TAGCCATATT	ATTCAATTGGT	TATATAGCAT	AAATCAATAT	4080
TGGCTATTGG	CCATTGCATA	CGTTGTATCC	ATATCATAAT	ATGTACATTT	ATATTGGCTC	4140
ATGTCCAACA	TTACCGCCAT	GTTGACATTG	ATTATTGACT	AGTTATTAAT	AGTAATCAAT	4200
TACGGGGTCA	TTAGTTCATA	GCCCATATAT	GGAGTTCGCG	GTTACATAAC	TTACGGTAAA	4260
TGGCCCGCCT	GGCTGACCGC	CCAACGACCC	CCGCCCATTG	ACGTCAATAA	TGACGTATGT	4320
TCCCATAGTA	ACGCCAATAG	GGACTTTCCA	TTGACGTCAA	TGGGTGGAGT	ATTTACGGTA	4380
AACTGCCCAC	TTGGCAGTAC	ATCAAGTGTA	TCATATGCCA	AGTACGCCCC	CTATTGACGT	4440
CAATGACGGT	AAATGGCCCC	CCTGGCATTG	TGCCCAGTAC	ATGACCTTAT	GGGACTTTCC	4500
TACTTGGCAG	TACATCTACG	TATTAGTCAT	CGCTATTACC	ATGGTGATGC	GGTTTTGGCA	4560
GTACATCAAT	GGGCGTGGAT	AGCGGTTTGA	CTCACGGGGA	TTTCCAAGTC	TCCACCCCAT	4620
TGACGTCAAT	GGGAGTTTGT	TTTGGCACCA	AAATCAACGG	GACTTTTCAA	AATGTCGTAA	4680
CAACTCCGCC	CCATTGACGC	AAATGGGCGG	TAGGCATGTA	CGGTGGGAGG	TCTATATAAG	4740
CAGAGCTCGT	TTAGTGAACC	GTCAGATCGC	CTGGAGACGC	CATCCACGCT	GTTTTGACCT	4800
CCATAGAAGA	CACCGGGACC	GATCCAGCCT	CCGCGGCCCC	AAGCTTCAGC	TGCTCGAGCC	4860
CGGGGATGAC	GTCATCGACT	TCGAAGGTTT	GAATCCTTCT	ACTGCCACCA	TTTTTTCTCT	4920
ACGTCATCGA	CTTCGAAGGT	TCGAATCCTT	CCCTGTCCAC	CAGTCGAGTA	TTACGTCATC	4980
GACTTCGAAG	GTTCTGAATCC	TTCTAGATTG	ACCATTTTTT	AGGAACGTCA	TCGACTTCGA	5040

AGGTTTGAAT	CCTTCCAGTT	CCACCAAGTCG	AGGCCAACGT	CATCGACTTC	GAAGGTTTGA	5100
ATCCTTCTCT	TCCCACCAT	TTTTTCCAC	GTCATCGACT	TCGAAGGTTT	GAATCCTTCG	5160
GGGCCCCACCA	GTCGAGGGCT	ACGTCATCGA	CTTCGAAGGT	TCGAATCCTT	CTTGCTTCAC	5220
CATTTTTTCT	GAACGTCATC	GACTTCGAAG	GTTTGAATCC	TTCTGCTGTC	ACCAGTCGAG	5280
TATAACGTCA	TCGACTTCGA	AGGTTTGAAT	CCTTCACCGG	TCACCATTTT	TTTATAACGT	5340
CATCGACTTC	GAAGGTTTGA	ATCCTTCTTC	TTACACCAAGT	CGAGGTACAC	GTCATCGACT	5400
TCGAAGGTTT	GAATCCTTCG	TAGTTTACCA	TTTTTTGTGC	ACGTCATCGA	CTTCGAAGGT	5460
TCGAATCCTT	CTAGGCCAC	CAGTCGACGC	ATGCCTGCAG	GTCGAGGTG	ATACCGTCGA	5520
GACCTAGAAA	AACATGGAGC	AATCACAAGT	AGCAATACAG	CAGCTACCAA	TGCTGATTGT	5580
GCCTGGCTAG	AAGCACAAGA	GGAGGAGGAG	GTGGGTTTTT	CAGTCACACC	TCAGGTACCT	5640
TTAAGACCAA	TGACTTACAA	GGCAGCTGTA	GATCTTAGCC	ACTTTTTAAA	AGAAAAGGGG	5700
GGACTGGAAG	GGCTAATTCA	CTCCCAACGA	AGACAAGATA	TCCTTGATCT	GTGGATCTAC	5760
CACACACAAG	GCTACTTCCC	TGATTGGCAG	AACTACACAC	CAGGGCCAGG	GATCAGATAT	5820
CCACTGACCT	TTGGATGGTG	CTACAAGCTA	GTACCAGTTG	AGCAAGAGAA	GGTAGAAGAA	5880
GCCAATGAAG	GAGAGAACAC	CCGCTTGTTA	CACCCTGTGA	GCCTGCATGG	GATGGATGAC	5940
CCGGAGAGAG	AAGTATTAGA	GTGGAGGTTT	GACAGCCGCC	TAGCATTTC	TCACATGGCC	6000
CGAGAGCTGC	ATCCGGAGTA	CTTCAAGAAC	TGCTGACATC	GAGCTTGCTA	CAAGGGACTT	6060
TCCGCTGGGG	ACTTTCCAGG	GAGGCGTGGC	CTGGGCGGGA	CTGGGGAGTG	GCGAGCCCTC	6120
AGATGCTGCA	TATAAGCAGC	TGCTTTTTGC	CTGTACTGGG	TCTCTCTGGT	TAGACCAGAT	6180
CTGAGCCTGG	GAGCTCTCTG	GCTAACTAGG	GAACCCACTG	CTTAAGCCTC	AATAAAGCTT	6240
GCCTTGAGTG	CTTCAAGTAG	TGTGTGCCCC	TCTGTTGTGT	GACTCTGGTA	ACTAGAGATC	6300
CCTCAGACCC	TTTTAGTCAG	TGTGGAAAAT	CTCTAGCAGT	CGAGGGGGGG	CCCGGTACCC	6360
AGCTTTTGTT	CCCTTTAGTG	AGGGTTAATT	GCGCGCTTGG	CGTAATCATG	GTCATAGCTG	6420
TTTCCTGTGT	GAAATTGTTA	TCCGCTCACA	ATTCCACACA	ACATACGAGC	CGGAAGCATA	6480
AAGTGTAAG	CCTGGGGTGC	CTAATGAGTG	AGCTAACTCA	CATTAATTGC	GTTGCGCTCA	6540
CTGCCCCGTT	TCCAGTCGGG	AAACCTGTGC	TGCCAGCTGC	ATTAATGAAT	CGGCCAACGC	6600
GCGGGGAGAG	GCGGTTTGCG	TATTGGGCGC	TCTTCCGCTT	CCTCGCTCAC	TGACTCGCTG	6660
CGCTCGGTG	TTCCGGCTGCG	GCGAGCGGTA	TCAGCTCACT	CAAAGGCGGT	AATACGGTTA	6720
TCCACAGAAT	CAGGGGATAA	CGCAGGAAAG	AACATGTGAG	CAAAAGGCCA	GCAAAAGGCC	6780
AGGAACCGTA	AAAAGGCCGC	GTTGCTGGCG	TTTTTCCATA	GGCTCCGCCC	CCCTGACGAG	6840
CATCACAAAA	ATCGACGCTC	AAGTCAGAGG	TGGCGAAACC	CGACAGGACT	ATAAAGATAC	6900
CAGGCGTTTC	CCCCTGGAAG	CTCCCTCGTG	CGCTCTCTCT	TTCCGACCCT	GCCGCTTACC	6960
GGATACCTGT	CCGCCTTTCT	CCCTTCGGGA	AGCGTGCGC	TTTCTCATAG	CTCACGCTGT	7020
AGGTATCTCA	GTTGCGGTGA	GGTCGTTTCG	TCCAAGCTGG	GCTGTGTGCA	CGAACCCCCC	7080
GTTCAGCCCG	ACCGCTGCGC	CTTATCCGGT	AACTATCGTC	TTGAGTCCAA	CCCGGTAAGA	7140
CACGACTTAT	CGCCACTGGC	AGCAGCCACT	GGTAACAGGA	TTAGCAGAGC	GAGGTATGTA	7200
GGCGGTGCTA	CAGAGTTCTT	GAAGTGGTGG	CCTAACTACG	GCTACACTAG	AAGGACAGTA	7260
TTTGGTATCT	GCGCTCTGCT	GAAGCCAGTT	ACCTTCGGAA	AAAGAGTTGG	TAGCTCTTGA	7320
TCCGGCAAAC	AAACCACCGC	TGGTAGCGGT	GGTTTTTTTG	TTTGCAAGCA	GCAGATTACG	7380
CGCAGAAAAA	AAGGATCTCA	AGAAGATCCT	TTGATCTTTT	CTACGGGGTC	TGACGCTCAG	7440
TGGAACGAAA	ACTCACGTTA	AGGGATTTTG	GTCATGAGAT	TATCAAAAAG	GATCTTCACC	7500
TAGATCCTTT	TAAATTAATA	ATGAAGTTTT	AAATCAATCT	AAAGTATATA	TGAGTAAACT	7560
TGGTCTGACA	GTTACCAATG	CTTAATCAGT	GAGGCACCTA	TCTCAGCGAT	CTGTCTATTT	7620
CGTTCATCCA	TAGTTGCCTG	ACTCCCCGTC	GTGTAGATAA	CTACGATACG	GGAGGGCTTA	7680
CCATCTGGCC	CCAGTGCTGC	AATGATACCG	CGAGACCCAC	GCTCACCGGC	TCCAGATTTA	7740
TCAGCAATAA	ACCAGCCAGC	CGGAAGGGCC	GAGCGCAGAA	GTGGTCCTGC	AACTTTATCC	7800
GCCTCCATCC	AGTCTATTAA	TTGTTGCCGG	GAAGCTAGAG	TAAGTAGTTC	GCCAGTTAAT	7860
AGTTTGCGCA	ACGTTGTTGC	CATTGCTACA	GGCATCGTGG	TGTCACGCTC	GTCGTTTGGT	7920

ATGGCTTCAT TCAGCTCCGG TTCCCAACGA TCAAGGCGAG TTACATGATC CCCCATGTTG 7980  
TGCAAAAAAG CGGTTAGCTC CTTCCGGTCCT CCGATCGTTG TCAGAAGTAA GTTGGCCGCA 8040  
GTGTTATCAC TCATGGTTAT GGCAGCACTG CATAATTCTC TTAGTGTCAT GCCATCCGTA 8100  
AGATGCTTTT CTGTGACTGG TGAGTACTCA ACCAAGTCAT TCTGAGAATA GTGTATGCGG 8160  
CGACCGAGTT GCTCTTGCCC GGCGTCAATA CGGGATAATA CCGCGCCACA TAGCAGAACT 8220  
TTAAAAGTGC TCATCATTGG AAAACGTTCT TCGGGGCGAA AACTCTCAAG GATCTTACCG 8280  
CTGTTGAGAT CCAGTTCGAT GTAACCCACT CGTGCACCCA ACTGATCTTC AGCATCTTTT 8340  
ACTTTCACCA GCGTTTCTGG GTGAGCAAAA ACAGGAAGGC AAAATGCCGC AAAAAAGGGA 8400  
ATAAGGGCGA CACGGAAATG TTGAATACTC ATACTCTTCC TTTTCAATA TTATTGAAGC 8460  
ATTTATCAGG GTTATTGTCT CATGAGCGGA TACATATTTG AATGTATTTA GAAAAATAAA 8520  
CAAATAGGGG TTCCGCGCAC ATTTCCCCGA AAAGTGCCAC 8560

CLAIMS

1. A viral vector system comprising:

(i) a first nucleotide sequence encoding an external guide sequence capable of binding to and effecting the cleavage by RNase P of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles; and

(ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that the third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by the external guide sequence.

2. A system according to claim 1 further comprising at least one further first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles, wherein the gene product is selected from an external guide sequence, a ribozyme and an anti-sense ribonucleic acid.

3. A viral vector production system comprising:

(i) a viral genome comprising at least one first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles;

(ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of the viral genome into viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that said third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by said gene product;

wherein at least one of the gene products is an external guide sequence capable of binding to and effecting the cleavage by RNase P of the second nucleotide sequence.

4. A system according to claim 3 wherein in addition to an external guide sequence, at least one gene product is selected from a ribozyme and an anti-sense ribonucleic acid.
5. A system according to any one of claims 1 to 4 wherein the viral vector is a retroviral vector.
6. A system according to claim 5 wherein the retroviral vector is a lentiviral vector.
7. A system according to claim 6 wherein the lentiviral vector is an HIV vector.
8. A system according to any one of claims 5 to 7 wherein the polypeptide required for the assembly of viral particles is selected from gag, pol and env proteins.
9. A system according to claim 8 wherein at least the gag and pol proteins are from a lentivirus.
10. A system according to claim 7 wherein the env protein is from a lentivirus.
11. A system according to claim 9 or 10 wherein the lentivirus is HIV.
12. A system according to any one of the preceding claims wherein the third nucleotide sequence is resistant to cleavage directed by the gene product as a result of one or more conservative alterations in the nucleotide sequence which remove cleavage sites recognised by the at least one gene product and/or binding sites for the at least one gene product
13. A system according to any one of claims 1 to 11 wherein the third nucleotide sequence is adapted to be resistant to cleavage by the at least one gene product.
14. A system according to any one of the preceding claims wherein the third nucleotide sequence is codon optimised for expression in producer cells.

15. A system according to claim 14, wherein the producer cells are mammalian cells.
16. A system according to any one of the preceding claims comprising a plurality of first nucleotide sequences and third nucleotide sequences as defined therein.
17. A viral particle comprising a viral vector genome as defined in any one of claims 3 to 16 and one or more third nucleotide sequences as defined in any of claims 3 to 16.
18. A viral particle produced using a viral vector production system according to any one of claims 3 to 16.
19. A method for producing a viral particle which method comprises introducing into a host cell (i) a viral genome as defined in any one of claims 3 to 16 (ii) one or more third nucleotide sequences as defined in any of claims 3 to 16 and (iii) nucleotide sequences encoding the other essential viral packaging components not encoded by the one or more third nucleotide sequences.
20. A viral particle produced by the method of claim 19.
21. A pharmaceutical composition comprising a viral particle according to claims 17, 18 or 20 together with a pharmaceutically acceptable carrier or diluent.
22. A viral system according to any one of claims 1 to 17 or a viral particle according to claims 17, 18 or 20 in treating a viral infection.
23. A viral system according to any one of claims 1 to 17 for use in a method of producing viral particles.

ABSTRACT

ANTI-VIRAL VECTORS

A viral vector production system is provided which system comprises:

- (i) a viral genome comprising at least one first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles;
- (ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of the viral genome into viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that said third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by said gene product;

wherein at least one of the gene products is an external guide sequence capable of binding to and effecting the cleavage by RNase P of the second nucleotide sequence.

5

The viral vector production system may be used to produce viral particles for use in treating or preventing viral infection.


THIS PAGE BLANK (USPTO)




Figure 1

pH4Rz

Plasmid




Integrated vector



Vector genomic  
RNA / Ribozyme  
Ribozyme

pH4.1Rz

Plasmid




Integrated vector




Vector genomic  
RNA / Ribozyme

pH6Rz

Plasmid



Integrated vector



Vector genomic  
RNA / Ribozyme  
Ribozyme

pH6.1Rz

Plasmid



Integrated vector




Vector genomic  
RNA / Ribozyme


THIS PAGE BLANK (USPTO)

figure 2

**A**



**B**



THIS PAGE BLANK (USPTO)

Figure 3

gagpol-HXB2 -> Codon Usage

DNA sequence 4308 b.p. ATGGGTGCGAGA ... GATGAGGATTAG linear

1436 codons

MW : 161929 Dalton CAI(S.c.) : 0.083 CAI(E.c.) : 0.151

TTT phe F	21	TCT ser S	3	TAT tyr Y	30	TGT cys C	18
TTC phe F	14	TCC ser S	3	TAC tyr Y	9	TGC cys C	2
TTA leu L	46	TCA ser S	19	TAA och Z	-	TGA opa Z	-
TTG leu L	11	TCG ser S	1	TAG amb Z	1	TGG trp W	37
CTT leu L	13	CCT pro P	21	CAT his H	20	CGT arg R	-
CTC leu L	7	CCC pro P	14	CAC his H	7	CGC arg R	-
CTA leu L	17	CCA pro P	41	CAA gln Q	56	CGA arg R	3
CTG leu L	16	CCG pro P	-	CAG gln Q	39	CGG arg R	3
ATT ile I	30	ACT thr T	24	AAT asn N	42	AGT ser S	18
ATC ile I	14	ACC thr T	20	AAC asn N	16	AGC ser S	16
ATA ile I	56	ACA thr T	43	AAA lys K	88	AGA arg R	45
ATG met M	29	ACG thr T	1	AAG lys K	34	AGG arg R	18
GTT val V	15	GCT ala A	17	GAT asp D	37	GGT gly G	11
GTC val V	11	GCC ala A	19	GAC asp D	26	GGC gly G	10
GTA val V	55	GCA ala A	55	GAA glu E	75	GGA gly G	61
GTG val V	15	GCG ala A	5	GAG glu E	32	GGG gly G	26

THIS PAGE BLANK (USPTO)

Figure 4

gaspol-SYNgp [1 to 4308] -> Codon Usage

DNA sequence 4308 b.p. ATGGGCGCCCGC ... GATGAGGATTAG linear

1436 codons

MW : 161929 Dalton CAI(S.c.) : 0.080 CAI(E.c.) : 0.296

TTT phe F	5	TCT ser S	5	TAT tyr Y	10	TGT cys C	6
TTC phe F	30	TCC ser S	11	TAC tyr Y	29	TGC cys C	14
TTA leu L	2	TCA ser S	4	TAA OCH Z	-	TGA OPA Z	-
TTG leu L	7	TCG ser S	6	TAG AMB Z	1	TGG trp W	37
CTT leu L	3	CCT pro P	14	CAT his H	6	CGT arg R	2
CTC leu L	22	CCC pro P	39	CAC his H	21	CGC arg R	34
CTA leu L	6	CCA pro P	10	CAA gln Q	14	CGA arg R	3
CTG leu L	70	CCG pro P	13	CAG gln Q	81	CGG arg R	10
ATT ile I	17	ACT thr T	11	AAT asn N	13	AGT ser S	7
ATC ile I	79	ACC thr T	48	AAC asn N	45	AGC ser S	27
ATA ile I	4	ACA thr T	13	AAA lys K	25	AGA arg R	7
ATG met M	29	ACG thr T	16	AAG lys K	97	AGG arg R	13
GTT val V	5	GCT ala A	15	GAT asp D	19	GGT gly G	10
GTC val V	27	GCC ala A	56	GAC asp D	44	GGC gly G	54
GTA val V	6	GCA ala A	13	GAA glu E	29	GGA gly G	16
GTG val V	58	GCG ala A	12	GAG glu E	78	GGG gly G	28

THIS PAGE BLANK (USPTO)



Figure 5

env-mn [1 to 2571] -> Codon Usage

DNA sequence 2571 b.p. ATGAGAGTGAAG ... GCTTTGCTATAA linear

857 codons

MW : 97078 Dalton CAI(S.c.) : 0.083 CAI(E.c.) : 0.140

TTT phe F	13	TCT ser S	7	TAT tyr Y	15	TGT cys C	16
TTC phe F	11	TCC ser S	3	TAC tyr Y	7	TGC cys C	5
TTA leu L	20	TCA ser S	13	TAA OCH Z	1	TGA OPA Z	-
TTG leu L	17	TCG ser S	2	TAG AMB Z	-	TGG trp W	30
CTT leu L	9	CCT pro P	5	CAT his H	8	CGT arg R	-
CTC leu L	11	CCC pro P	9	CAC his H	6	CGC arg R	2
CTA leu L	12	CCA pro P	12	CAA gln Q	22	CGA arg R	1
CTG leu L	15	CCG pro P	2	CAG gln Q	19	CGG arg R	1
ATT ile I	21	ACT thr T	16	AAT asn N	50	AGT ser S	18
ATC ile I	10	ACC thr T	14	AAC asn N	13	AGC ser S	11
ATA ile I	32	ACA thr T	28	AAA lys K	32	AGA arg R	30
ATG met M	17	ACG thr T	5	AAG lys K	14	AGG arg R	15
GTT val V	8	GCT ala A	16	GAT asp D	18	GGT gly G	10
GTC val V	9	GCC ala A	7	GAC asp D	14	GGC gly G	6
GTA val V	26	GCA ala A	20	GAA glu E	36	GGA gly G	28
GTG val V	12	GCG ala A	5	GAG glu E	10	GGG gly G	12

THIS PAGE BLANK (USPTO)

Figure 6

SYNGp160mn -> Codon Usage

DNA sequence 2571 b.p. ATGAGGGTGAAG ... GCGCTGCTGTAA linear

857 codons


MW : 97078 Dalton CAI(S.c.) : 0.074 CAI(E.c.) : 0.419

TTT phe F	-	TCT ser S	2	TAT tyr Y	1	TGT cys C	-
TTC phe F	24	TCC ser S	4	TAC tyr Y	21	TGC cys C	21
TTA leu L	-	TCA ser S	-	TAA och Z	1	TGA opa Z	-
TTG leu L	-	TCG ser S	-	TAG amb Z	-	TGG trp W	30
CTT leu L	-	CCT pro P	-	CAT his H	2	CGT arg R	1
CTC leu L	20	CCC pro P	26	CAC his H	12	CGC arg R	36
CTA leu L	1	CCA pro P	-	CAA gln Q	-	CGA arg R	-
CTG leu L	63	CCG pro P	2	CAG gln Q	41	CGG arg R	4
ATT ile I	2	ACT thr T	-	AAT asn N	2	AGT ser S	-
ATC ile I	61	ACC thr T	59	AAC asn N	61	AGC ser S	48
ATA ile I	-	ACA thr T	-	AAA lys K	1	AGA arg R	2
ATG met M	17	ACG thr T	4	AAG lys K	45	AGG arg R	6
GTT val V	-	GCT ala A	-	GAT asp D	2	GGT gly G	1
GTC val V	1	GCC ala A	40	GAC asp D	30	GGC gly G	47
GTA val V	1	GCA ala A	-	GAA glu E	3	GGA gly G	-
GTG val V	53	GCG ala A	8	GAG glu E	43	GGG gly G	8



Figure 7

# HIV Constructs






11/11/2020

11/11/2020

Figure 8

# The Hit Vector System

## Helper packaging cell lines



## Three-plasmid cotransfection (HIT)









Figure 9 A





EGS Based on Tyrosyl t-RNA



**Figure 9 B**

Generic design of EGSs to target any RNA.







1999

1999

Figure 10 A





[illegible]

A

C C C A

Target 5' - A  
(HXB2 2005) G - C

g - c g - c g - c c - g c - g c - g c - g

EGS

c - g c - g UA

U CUUCC A

a ||||| G

3'-aagg GAAGG C

||||| C UU

5'-ttcc U U

A ,C C ,A U ,G C C AU

```

      A
      C
      C
      A
Target 5' - (HXB2 2091) G - C
                    g - c
                    g - c
                    a - u
                    a - u
                    g - c
                    a - u
                    U
      CUUCC A
      ||||| G
      GAAGG C
      C UU
      U
      A
      C
      ,C
      G,A
      U,G
      C,C
      AU
EGS

```





Figure 10 C







Figure 11



7/4800/01002

D Yang+Co

17/3/00

THIS PAGE BLANK (USPTO)